A Phase II, Open Label, Multicenter Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in Patients With Relapsed/Refractory CD38 Positive Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal Lymphomas of TFH Cell Origin
Phase: PHASE2
Conditions: Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
Sponsor: Fondazione Italiana Linfomi - ETS

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Pag 1 di 79 
 
 
 
 
 
 
Clinical Protocol 
 
 
A phase II, open label, multicenter trial of Daratumumab in combination with 
Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with relapsed/refractory 
CD38 positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), 
angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of TFH cell 
origin 
 
ID Study: FIL_Dara-GDP 
EudraCT number: 2018-002644-91 
INVESTIGATOR SPONSOR: 
Fondazione Italiana Linfomi ONLUS (FIL) 
 
COORDINATING INVESTIGATOR 
Francesco Zaja, Trieste, Italy 
WRITING COMMITTEE AND SCIENTIFIC 
SUPPORT 
Francesco Zaja, Trieste, Italy 
Marzia Varettoni, Pavia, Italy 
Annalisa Chiappella, Torino, Italy  
Stefano Pileri, Milano, Italy 
Giovannino Ciccone, Torino, Italy  
 
REGISTRATION (REFER TO CHAPTER 12) 
www.filinf.it 
SAE REPORTING (REFER TO CHAPTER 17) 
www.drugvigilance.filinf.it/ 
 
 
 
Version and date of Protocol: Version 1.0 of March 29, 2019 
 
 
 
 
CONFIDENTIALITY STATEMENT 
The information contained in this document is the property of Fondazione Italiana Linfomi Onlus (FIL) and therefore 
is provided to you in confidence for review by you, your staff, an applicable Ethics Committee and regulatory 
authorities. It is understood that the information will not be disclosed to others without prior written approval from 
the Fondazione Italiana Linfomi Onlus (FIL), except to the extent necessary to obtain informed consent from those 
persons to whom the medication may be administered. 
 
 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 2 of 79 
 
RESPONSIBILITIES 
 
SPONSOR 
 : Fondazione Italiana Linfomi (FIL) 
 : +39.0131.033151 Fax: +39.0131.263455 
Email: segreteriadirezione@filinf.it 
 
COORDINATING INVESTIGATOR 
 : Prof. Francesco Zaja  
S.C. Ematologia, Azienda Sanitaria Universitaria Integrata, Trieste 
☎ : + 39 040 3992015  
Email : francesco.zaja@asuits.sanita.fvg.it  
 
WRITING COMMITTEE 
 : Prof. Francesco Zaja  
S.C. Ematologia, Azienda Sanitaria Universitaria Integrata, Trieste 
☎ : + 39 040 3992015  
Email : francesco.zaja@asuits.sanita.fvg.it  
 
 : Dr.ssa Marzia Varettoni, Dipartimento di Ematologia e Oncologia, IRCCS Policlinico San Matteo, Pavia 
 : +39 0382 503082 Fax: 
+39 0382 503082 
Email : m.varettoni@smatteo.pv.it 
 
 : Dr.ssa Annalisa Chiappella, Ematologia, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di 
Torino, C.so Bramante 88, 10126 Torino 
 : +39.011.6335611 Fax: +39.011.6335611 
 
Email: achiappella@cittadellasalute.to.it 
 
 : Stefano Pileri, Divisione di Diagnosi Emolinfopatologica, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 
Milano 
 : +39.02.57489770 Fax: +39.02.94379320  
Email: stefano.pileri@ieo.it 
 : Giovannino Ciccone, SSD Epidemiologia clinica e valutativa-CPO Piemonte, Via Santena 7, 10126 Torino 
 : +39.011. 6336857 Fax: +39.011.6334664 
Email:  gianni.ciccone@cpo.it; statistica@filinf.it 
 
COORDINATING PATHOLOGISTS 
 : Stefano Pileri, Divisione di Diagnosi Emolinfopatologica, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 
Milano 
 : +39.02.57489770 Fax: +39.02.94379320  
Email: stefano.pileri@ieo.it; divisione.emolinfopatologia@ieo.it 
 
PHARMACOVIGILANCE 
 : Ufficio Farmacovigilanza, Uffici Studi FIL, Fondazione Italiana Linfomi Onlus c/o Uffici PACTO, Spalto Marengo 
44, 15121 Alessandria 
 : +39.0131.033156 Fax: +39.0131.263455 
Email: drugvigilance@filinf.it 
 
START UP 
 : Uffici Studi FIL, Fondazione Italiana Linfomi Onlus c/o Uffici PACTO, Spalto Marengo 44, 15121 Alessandria 
 : +39.0131.033153 Fax: +39.0131.263455 
Email: startup@filinf.it 
 
STUDY COORDINATOR 
 : Area Gestione Studi, Uffici Studi FIL, Fondazione Italiana Linfomi Onlus c/o Uffici PACTO, Spalto Marengo 44, 
15121 Alessandria 
 : +39.0131.033154 Fax: +39.0131.263455 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 3 of 79 
Email: cperacchio@filinf.it; gestionestudi@filinf.it 
 
COORDINATING STATISTICIANS 
 : Giovannino Ciccone, SSD Epidemiologia clinica e valutativa-CPO Piemonte, Via Santena 7, 10126 Torino 
 : +39.011.6336857 Fax: +39.011.6334664 
Email: gianni.ciccone@cpo.it; statistica@filinf.it 
 : Chiara Monagheddu, SSD Epidemiologia clinica e valutativa-CPO Piemonte, Via Santena 7, 10126 Torino 
 : +39.011.6336854     Fax: +39.011.6334664 
Email: chiara.monagheddu@cpo.it; statistica@filinf.it 
 
SUPPORT IN PROTOCOL DRAFTING 
 : Monica Bellei, Uffici Studi FIL, Fondazione Italiana Linfomi Onlus c/o Dipartimento di Scienze Mediche e 
Chirurgiche Materno-Infantili e dell'Adulto, Centro Oncologico Modenese, via del Pozzo 71, 41124 Modena 
 : +39-059-4224020 Fax: +39-059-4223602 
Email: mbellei@filinf.it; redazioneprotocolli@filinf.it 
 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 4 of 79 
 
TABLE OF CONTENTS 
 
RESPONSIBILITIES ....................................................................................................... 2 
 
SPONSOR ....................................................................................................................... 2 
 
COORDINATING INVESTIGATOR ........................................................................................ 2 
 
WRITING COMMITTEE ...................................................................................................... 2 
 
COORDINATING PATHOLOGISTS ....................................................................................... 2 
 
PHARMACOVIGILANCE ..................................................................................................... 2 
 
START UP ....................................................................................................................... 2 
 
STUDY COORDINATOR..................................................................................................... 2 
 
COORDINATING STATISTICIANS ........................................................................................ 3 
 
SUPPORT IN PROTOCOL DRAFTING ................................................................................... 3 
 
TABLE OF CONTENTS .................................................................................................. 4 
 
INVESTIGATOR AGREEMENT ...................................................................................... 9 
 
SYNOPSIS .................................................................................................................... 10 
 
LIST OF ABBREVIATIONS AND GLOSSARY OF TERMS ......................................... 17 
 
STUDY FLOW CHART ................................................................................................. 19 
 
BACKGROUND ............................................................................................................ 20 
 
OVERVIEW OF PERIPHERAL T-CELL LYMPHOMAS ............................................................. 20 
 
CURRENT THERAPIES FOR RELAPSED REFRACTORY PTCLS ............................................ 20 
 
STUDY DRUG BACKGROUND: DARATUMUMAB .................................................................. 21 
 
Mechanism of action ................................................................................................... 21 
 
PRECLINICAL STUDIES ................................................................................................... 22 
 
Pharmacodynamics .................................................................................................... 22 
 
Non-clinical toxicology: Carcinogenesis, Mutagenesis, Impairment of Fertility .......... 22 
 
Animal Toxicology ...................................................................................................... 22 
 
CLINICAL PHARMACOLOGY ............................................................................................ 22 
 
Pharmacodynamics .................................................................................................... 22 
 
Pharmacokinetics ....................................................................................................... 22 
7.5.2.1. 
Distribution ............................................................................................................................................... 23 
7.5.2.2. 
Elimination ............................................................................................................................................... 23 
7.5.2.3. 
Special populations .................................................................................................................................. 23 
7.5.2.4. 
Drug Interactions ...................................................................................................................................... 23 
 
CLINICAL TRIALS ........................................................................................................... 23 
 
Relapsed/Refractory Multiple Myeloma ...................................................................... 23 
 
Newly Diagnosed Multiple Myeloma .......................................................................... 25 
 
Clinical Activity in other hematological malignancies ................................................. 25 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 5 of 79 
 
STUDY RATIONALE .................................................................................................... 26 
 
STUDY OBJECTIVES................................................................................................... 27 
 
PRIMARY OBJECTIVE ..................................................................................................... 27 
 
SECONDARY OBJECTIVES .............................................................................................. 27 
 
EXPLORATIVE OBJECTIVES ............................................................................................ 27 
 STUDY DESIGN ........................................................................................................... 27 
 
OVERVIEW OF STUDY DESIGN ........................................................................................ 27 
 
NUMBER OF PATIENTS ................................................................................................... 28 
 
DURATION OF THE STUDY .............................................................................................. 28 
 STUDY POPULATION .................................................................................................. 28 
 
INCLUSION CRITERIA ..................................................................................................... 28 
 
EXCLUSION CRITERIA .................................................................................................... 29 
 PATIENTS ENROLLMENT ........................................................................................... 30 
 
INFORMED CONSENT ..................................................................................................... 30 
 
PATIENT REGISTRATION AND DATA COLLECTION .............................................................. 30 
 TREATMENT ................................................................................................................ 31 
 
TREATMENT SCHEDULE AND DESIGN ............................................................................. 31 
 
Pre- and Post- infusion Medications ........................................................................... 31 
 
Treatment during induction phase .............................................................................. 31 
 
Treatment during maintenance phase ........................................................................ 32 
 
Treatment discontinuation .......................................................................................... 32 
 
DARATUMUMAB ............................................................................................................. 32 
 
Supplier....................................................................................................................... 32 
 
Dosage form, packaging and labeling ........................................................................ 32 
 
Receipt of study drug .................................................................................................. 32 
 
Storage and handling ................................................................................................. 32 
 
Unused study drug supplies ....................................................................................... 33 
 
ADMITTED/EXCLUDED CONCOMITANT MEDICATION .......................................................... 33 
 
Recommended concomitant medications .................................................................. 33 
 
Other concomitant admitted medications ................................................................... 34 
 
Excluded medications ................................................................................................. 34 
 
PROPHYLACTIC MEASURES ............................................................................................ 34 
 
Hospitalization during the first cycle of therapy .......................................................... 34 
 
Prevention of daratumumab infusion-related reactions (IRRs) .................................. 34 
 
Prophylaxis for tumor lysis syndrome (TLS) ............................................................... 35 
 
Mandatory primary neutropenia prophylaxis .............................................................. 35 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 6 of 79 
 
Prevention of Herpes Zoster infection and Pneumocystis Jiroveci Pneumonia ......... 35 
 
Anti-Hyperuricemic therapy ........................................................................................ 35 
 
Prevention and Management of Hepatitis B Virus Reactivation................................. 35 
 
HCV positive patients ................................................................................................. 36 
 
CONTRACEPTION .......................................................................................................... 36 
 
GDP TOXICITY ............................................................................................................. 37 
 
DARATUMUMAB TOXICITY .............................................................................................. 38 
 
Indications and Use .................................................................................................... 38 
 
Contraindications ........................................................................................................ 38 
 
Special warnings and precautions for use of daratumumab ...................................... 39 
 
Adverse Drug Reactions ............................................................................................. 40 
 
Special Populations .................................................................................................... 40 
 
Fertility, pregnancy and lactation ................................................................................ 41 
 
Interaction with other medicinal products and other forms of interaction ................... 41 
 
DRUGS DOSE MODIFICATION .......................................................................................... 41 
 
GDP ............................................................................................................................ 41 
 
Daratumumab ............................................................................................................. 42 
 REMOVAL OF SUBJECTS FROM TREATMENT AND/OR STUDY ............................ 42 
 
DISCONTINUATION FROM STUDY TREATMENT .................................................................. 42 
 
WITHDRAWAL OF SUBJECTS FROM THE STUDY ................................................................ 42 
 
WITHDRAWAL OF CONSENT ........................................................................................... 43 
 
PATIENTS LOST TO FOLLOW UP ..................................................................................... 43 
 
PREMATURE TERMINATION OF THE STUDY ...................................................................... 43 
 STUDY PROCEDURES TIMEPOINTS ......................................................................... 43 
 
SCREENING PERIOD ...................................................................................................... 43 
 
INDUCTION PHASE ......................................................................................................... 44 
 
MAINTENANCE PHASE.................................................................................................... 45 
 
HBV STUDY EVALUATIONS ............................................................................................ 45 
 
RESTAGING AFTER 4 COURSES OF INDUCTION ................................................................ 45 
 
RESTAGING AT EOI (END OF INDUCTION PHASE) ............................................................. 46 
 
RESTAGING DURING MAINTENANCE ................................................................................ 46 
 
RESTAGING AT THE EOT (REGARDLESS OF THE REASON FOR DISCONTINUATION) ............. 46 
 
ASSESSMENTS DURING FOLLOW-UP ............................................................................... 47 
 
SCHEDULE OF ASSESSMENTS ........................................................................................ 48 
 EFFICACY MEASUREMENTS AND PARAMETERS .................................................. 50 
 
EFFICACY MEASUREMENT .............................................................................................. 50 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 7 of 79 
 
EFFICACY PARAMETERS ................................................................................................ 50 
 
Primary efficacy endpoint ........................................................................................... 50 
 
Secondary efficacy endpoints .................................................................................... 50 
 
Explorative efficacy endpoints .................................................................................... 50 
 SAFETY MEASUREMENTS AND PARAMETERS ...................................................... 51 
 
SAFETY MEASUREMENTS ............................................................................................... 51 
 
Definition of relevant toxicity ....................................................................................... 51 
 
SAFETY PARAMETERS ................................................................................................... 51 
 
Adverse Events (AEs) and Adverse Drug Reactions (ADRs) .................................... 51 
 
Serious Adverse Events (SAE) .................................................................................. 52 
 
Suspected Unexpected Serious Adverse Reaction (SUSAR).................................... 53 
 
Severity ....................................................................................................................... 53 
 
Causality ..................................................................................................................... 53 
 
SERIOUS ADVERSE EVENTS REPORTING RULES .............................................................. 54 
 
Obligations of the Investigator .................................................................................... 55 
 
Obligations of the Sponsor ......................................................................................... 56 
 
PREGNANCY ................................................................................................................. 57 
 
Females of Childbearing Potential ............................................................................. 57 
 
Male patients .............................................................................................................. 58 
 
FOLLOW UP OF AES AND SAES ..................................................................................... 58 
 
PRODUCT QUALITY COMPLAINT HANDLING ..................................................................... 58 
 STATISTICAL CONSIDERATIONS .............................................................................. 58 
 
STUDY DESIGN .............................................................................................................. 58 
 
SAMPLE SIZE CALCULATION ........................................................................................... 58 
 
SAFETY MONITORING AND STOPPING RULES ................................................................... 59 
 
STATISTICAL ANALYSIS PLAN .......................................................................................... 59 
 
Analysis population ..................................................................................................... 59 
 
Demographics and other baseline characteristics ..................................................... 59 
 
Final Efficacy analysis ................................................................................................ 60 
 
Final Safety analysis ................................................................................................... 60 
 
Final analysis .............................................................................................................. 60 
 INDEPENDENT DATA SAFETY MONITORING BOARD (DSMB) .............................. 60 
 INDEPENDENT EXTERNAL PATHOLOGY REVIEW .................................................. 61 
 GOOD CLINICAL PRACTICE, QUALITY CONTROL & QUALITY ASSURANCE ...... 61 
 
MONITORING, AUDITS AND INSPECTIONS ........................................................................ 61 
 
INVESTIGATOR(S) RESPONSIBILITIES .............................................................................. 62 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 8 of 79 
 ETHICAL AND REGULATORY STANDARDS ............................................................. 62 
 
INDEPENDENT ETHICS COMMITTEE REVIEW APPROVAL ................................................... 62 
 
PROTOCOL AMENDMENTS APPROVAL............................................................................. 63 
 ADMINISTRATIVE PROCEDURES .............................................................................. 64 
 
CURRICULUM VITAE ....................................................................................................... 64 
 
CONFIDENTIALITY AGREEMENT ...................................................................................... 64 
 
RECORD RETENTION IN INVESTIGATING CENTERS ............................................................ 64 
 
OWNERSHIP OF DATA AND USE OF THE STUDY RESULTS................................................. 64 
 
AUTHORSHIP ................................................................................................................ 64 
 
INSURANCE COVERAGE ................................................................................................. 65 
 
PROTOCOL AMENDMENTS PROCEDURES ......................................................................... 65 
 DATA HANDLING AND RECORD KEEPING .............................................................. 65 
 
DATA/DOCUMENTS ....................................................................................................... 65 
 
DATA MANAGEMENT ..................................................................................................... 65 
 
RETENTION OF RECORDS .............................................................................................. 66 
 PRIVACY OF PERSONAL DATA ................................................................................. 66 
 REFERENCES .............................................................................................................. 67 
 APPENDICES ............................................................................................................... 70 
APPENDIX A: 
ECOG PERFORMANCE STATUS...................................................................... 70 
APPENDIX B: 
CREATININE CLEARANCE CALCULATION .......................................................... 71 
APPENDIX C: 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS V. 5.0 .................... 72 
APPENDIX D: 
RESPONSE ASSESSMENT BY CT AND PET SCANS ............................................ 73 
APPENDIX E: 
GUIDELINES FOR PATHOLOGY REVIEW ............................................................ 75 
APPENDIX F: 
REFERENCE SAFETY INFORMATION DARATUMUMAB ........................................ 77 
 
 
 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 9 of 79 
 
INVESTIGATOR AGREEMENT 
 
I have read this protocol and agree that it contains all necessary details for carrying out this study. I will 
conduct the study as outlined herein and will complete the study within the time designated. 
I will provide copies of the protocol and all pertinent information to all individuals responsible to me who 
assist in the conduct of this study. I will discuss this material with them to ensure that they are fully informed 
regarding the study drug and the conduct of the study. 
 
______________________________________________ 
Investigator’s Signature 
Date 
 
______________________________________________ 
Name of Investigator (Typed or Printed) 
 
______________________________________________ 
______________________________________________ 
______________________________________________ 
Institution, Address* 
 
______________________________________________ 
Phone Number* 
 
 
______________________________________________ 
Investigator-Sponsor Signature* 
Date 
(where required) 
_______________________________________________ 
Name of Coordinating Investigator (Typed or Printed) 
 
________________________________________________ 
Institution 
 
* If the address or phone number of the investigator changes during the course of the study, written 
notification will be provided by the investigator to the sponsor and will not require protocol amendment(s). 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 10 of 79 
 
SYNOPSIS 
Study ID 
FIL_Dara-GDP 
EudraCT N° 
2018-002644-91 
Title of the study 
A phase II, open label, multicenter trial of Daratumumab in combination with 
Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with 
relapsed/refractory CD38 positive peripheral T-cell lymphoma not otherwise 
specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other 
nodal lymphomas of TFH cell origin 
Phase of the study 
Prospective, multicenter, phase II single arm study. 
Investigational 
product 
Daratumumab 
Protocol version 
Version 1.0 of March 29, 2019 
Centers 
20 centers in Italy part of Fondazione Italiana Linfomi 
Study Objectives 
and 
Endpoints 
Primary Objective 
To evaluate the efficacy of 4 courses of D-GDP in terms of complete response 
in patients with PTCL-NOS, AILT and other nodal lymphomas of TFH cell origin 
refractory/relapsed after at least one and no more than two previous lines of 
therapy. 
Secondary Objectives 
- 
To evaluate the Overall Response Rate (ORR) (Lugano 2014); 
- 
To evaluate the efficacy in terms of Overall survival (OS); 
- 
To evaluate the efficacy in terms of Progression-free survival (PFS); 
- 
To evaluate the safety of D-GDP combination. 
Explorative objectives 
- 
To assess the role of daratumumab maintenance; 
- 
To evaluate the association between intensity of CD38 expression and 
response.  
 
Primary Endpoint 
CR (Complete Response) Rate (CRR) after 4 cycles of D-GDP. CR will be 
defined according to the Lugano 2014 criteria 
Secondary Endpoints 
1) ORR (=CR + Partial Response, PR) (Lugano 2014) 
2) OS (defined as the time from treatment start and death from any cause) 
(Lugano 2014) 
3) PFS (defined as the time from treatment start and progression/relapse or 
death from any cause) (Lugano 2014) 
4) The occurrence of relevant toxicity evaluated in terms of: 
- 
grade 4 neutropenia lasting for more than 7 days regardless adequate 
G-CSF primary prophylaxis/treatment 
- 
grade 4 thrombocytopenia lasting for more than 7 days 
- 
delay ≥ 15 days in the next course administration 
- 
any relevant grade 3-4 non-hematological toxicity drug related (excluding 
alopecia, laboratoristic data and infusion-related reaction, IRR); 
- 
febrile neutropenia lasting for more than 7 consecutive days 
Toxicity will be recorded and classified according to the definitions of the NCI 
criteria “Common Terminology Criteria for Adverse Events (CTCAE)”, version 
5.0.  
 
 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 11 of 79 
Explorative efficacy endpoints 
- 
Role of daratumumab maintenance by comparison of CRR before and 
after maintenance, and by evaluation of rate of conversion in CR with 
daratumumab maintenance for patients in PR after the induction. 
- 
Association between intensity of CD38 expression and response. The 
extent of CD38 expression evaluated by the central FIL designed 
laboratory will be correlated with response measured according to the 
Lugano 2014 criteria at various timepoints. 
Study design 
This is an open-label, multicenter, single arm, single-stage phase II trial. 
After the patient signs the written informed consent the patient will enter the 
screening phase planning baseline assessments and a concomitant upfront 
confirmation of diagnosis of PTCL-NOS, AITL or nodal lymphoma of TFH cell 
origin and a central evaluation of immunohistochemical positivity of CD38 on 
bioptic material used to perform local diagnosis of relapsed disease, or that used 
for the more recent biopsy in the case of refractory patients. A core needle biopsy 
is considered sufficient for review and CD38 evaluation. Evaluation at central 
laboratory can be performed  in bone marrow sections in those patients with only 
bone marrow lymphoma infiltration. 
Only patients with confirmed eligible diagnosis and a percentage of CD38 
positive tumor cells ≥ 5% will be considered eligible for study treatment.  
The treatment consists of an induction phase and a maintenance phase. 
Induction phase:  
4-6 courses (according to response after cycle 4 and to patient compliance) of 
D-GDP every 21 days pursuant to the following schedule: 
• 
Daratumumab cycle 1: 8 mg/kg i.v. on day 2 and on day 9; cycle 2-6: 16 
mg/kg i.v. on day 2 and day 9) 
• 
Gemcitabine 1000 mg/sm i.v. day 1 and day 8 (gemcitabine on day 8 to 
be skipped in case of grade 3-4 toxicity) 
• 
Cisplatin 75 mg/sm i.v. day 1 
• 
Dexamethasone 40 mg i.v. or po days 1-2-3-4-9 
• 
G-CSF from day 3 to 6, and from day 10 to 13 (to be prolonged if 
necessary) 
 
After 4 courses of D-GDP, patients in CR/PR and eligible for allogeneic stem cell 
transplantation (allo-SCT) will be addressed to allo-SCT consolidation. 
Otherwise, patients in CR will enter the maintenance phase at this point of the 
study.  
Patients in PR (not eligible for allogeneic stem cell transplantation) or in SD after 
D-GDP x 4 can receive 2 additional courses of D-GDP before maintenance or 
can move directly to maintenance, according to center choice (based on patient 
condition, performance status and quality of response).  
Patients who respond (CR/PR) after 6 courses of induction phase (end of 
induction, EOI) and eligible to allo-SCT will be addressed to allo-SCT 
consolidation.  
Patients who respond to the induction phase (CR/PR) and are not eligible for 
allo-SCT and patients in SD at EOI, will move to the maintenance phase. 
Patients in PD at any time will discontinue treatment, as well as patients 
experiencing at any time unacceptable toxicity.  
 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 12 of 79 
Maintenance phase:  
starting 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade 
> 1, after toxicity is resolved) and up to 24 cycles from start of D-GDP according 
to the following schedule:  
• 
Daratumumab 16 mg/kg single administration every 28 days 
 
Treatment with D-GDP or daratumumab single agent will be discontinued before 
completion of 24 cycles in case of: 
• 
decision of the investigator to consolidate D-GDP response with 
allogeneic stem cell transplant 
• 
disease progression 
• 
unacceptable toxicity 
• 
withdrawal of consent 
• 
investigator determines that further therapy is not in the patient’s best 
interest (e.g., due to non-compliance, toxicity, etc.) 
Adverse events (CTCAE v. 5.0) will be monitored from the first study-related 
procedure, throughout treatment, maintenance and for 30 days after the end of 
treatment with the study drug. 
Duration of the 
study 
Patients will be recruited over 18 months. The median expected duration of the 
treatment period is approximately 6 months. End of study is defined by the visit 
planned by the protocol 24 months after the start of treatment of the last patient, 
for a total study duration of approximately 42 months (3.5 years). 
Number of patients A total of 35 patients will be enrolled in the study.  
Inclusion criteria 
• 
Histologically documented diagnosis of CD38 positive PTCL-NOS, AITL and 
other nodal lymphomas of TFH cell origin as defined in the 2017 edition of 
the World Health Organization (WHO) classification. Patients with only bone 
marrow involvement are eligible. 
Note: Only patients with a centrally assessed percentage of CD38 positive 
tumor cells ≥ 5% in the relapse biopsy, or in the more recent biopsy in the 
case of refractory patients, will be considered eligible for protocol study 
treatment.  
• 
Age 18-75 years 
• 
Relapsed or refractory to at least one and a maximum of two previous lines 
of treatment 
• 
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 
• 
At least one site of measurable nodal disease at baseline ≥ 2.0 cm  in the 
longest transverse diameter as determined by CT scan (MRI is allowed only 
if CT scan cannot be performed). Note: Patients with only bone marrow 
involvement are eligible 
• 
Adequate hematological counts defined as follows: 
- 
Absolute Neutrophil count (ANC) > 1.0 x 109/L unless due to bone 
marrow involvement by lymphoma 
- 
Platelet count ≥ 50.000/mm3 unless due to bone marrow involvement by 
lymphoma 
• 
Adequate renal function defined as follows: 
- 
Creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula) 
• 
Adequate hepatic function per local laboratory reference range as follows: 
- 
Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x 
ULN  
- 
Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert’s syndrome or 
of non-hepatic origin)  

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 13 of 79 
• 
Subject understands and voluntarily signs an informed consent form 
approved by an Independent Ethics Committee (IEC), prior to the initiation of 
any screening or study-specific procedures 
• 
Subject must be able to adhere to the study visit schedule and other protocol 
requirements 
• 
Life expectancy ≥ 3 months 
• 
Women must be: 
- 
postmenopausal for at least 1 year (must not have had a natural menses 
for at least 12 months) 
- 
surgically sterile (have had a hysterectomy or bilateral oophorectomy, 
tubal ligation, or otherwise be incapable of pregnancy), 
- 
completely abstinent (periodic abstinence from intercourse is not 
permitted) or if sexually active, be practicing two highly effective 
methods of birth control (e.g., prescription oral contraceptives, 
contraceptive injections, contraceptive patch, intrauterine device, double 
barrier method (e.g.: condoms, diaphragm, or cervical cap, with 
spermicidal foam, cream, or gel, male partner sterilization) as local 
regulations permit, before entry, and must agree to continue to use the 
same method of contraception throughout the study. They must also be 
prepared to continue birth control measures for at least 3 months after 
terminating treatment. 
- 
Women of childbearing potential must have a negative pregnancy test 
at screening 
• 
Men must agree to use an acceptable method of contraception (for 
themselves or female partners as listed above) for the duration of the study. 
Men must agree to use a double barrier method of birth control and to not 
donate sperm during the study and for 3 months after receiving the last dose 
of study drug. 
• 
Male even if surgically sterilized (i.e., status post vasectomy) must agree to 
1 of the following: 
- 
practice effective barrier contraception during the entire study treatment 
period and through 3 months after the last dose of study drug, or 
- 
agree to practice true abstinence, when this is in line with the preferred 
and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, 
ovulation, symptothermal, post ovulation methods for the female partner] 
and withdrawal are not acceptable methods of contraception) 
Exclusion criteria 
• 
Histological diagnosis different from CD38 positive PTCL-NOS, AITL, and 
other nodal lymphomas of TFH cell origin 
• 
More than two lines of previous treatment (autologous stem cell transplant 
performed as part of consolidation to a previous line of therapy should not be 
considered as a line of therapy) 
• 
Previous treatment with Gemcitabine or Platinum based regimens; patients 
who received a single course of Platinum based course (i.e. DHAP) are not 
excluded 
• 
Prior therapy with monoclonal antibody antiCD38 
• 
Concomitant experimental therapy 
• 
Relapse after allo SCT 
• 
CNS involvement with lymphoma 
• 
Subject has received any anti-cancer therapy including chemotherapy, 
immunotherapy, radiotherapy, investigational therapy, including targeted 
small molecule agents within 14 days prior to the first dose of study drug 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 14 of 79 
• 
Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment 
• 
Subject is: 
- 
Known to be seropositive for human immunodeficiency virus (HIV) 
- 
Seropositive for hepatitis B (defined by a positive test for hepatitis B 
surface antigen [HBsAg]). Subjects with resolved infection (i.e., subjects 
who are HBsAg negative but positive for antibodies to hepatitis B core 
antigen [anti-HBc] ± antibodies to hepatitis B surface antigen [anti-HBs]) 
must be screened using real-time polymerase chain reaction (PCR) 
measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR 
positive will be excluded. EXCEPTION: Subjects with serologic findings 
suggestive of HBV vaccination (anti-HBs positivity as the only serologic 
marker) AND a known history of prior HBV vaccination, do not need to 
be tested for HBV DNA by PCR 
- 
Known to be seropositive for hepatitis C (except in the setting of a 
sustained virologic response [SVR], defined as aviremia at least 12 
weeks after completion of antiviral therapy) 
• 
Cardiovascular disease (NYHA class ≥2) 
• 
Creatinine Clearance < 40 mL/min (Cockcroft–Gault formula) 
• 
Significant history of neurologic, psychiatric, endocrinological, metabolic, 
immunologic, or hepatic disease that would preclude participation in the 
study or compromise ability to give informed consent 
• 
Any history of other active malignancies within 3 years prior to study entry, 
with the exception of adequately treated in situ carcinoma of the cervix 
uterine, basal cell carcinoma of the skin or localized squamous cell 
carcinoma of the skin, previous malignancy confined and surgically resected 
with curative intent. 
• 
Uncontrolled and/or active systemic infection (viral, bacterial or fungal) 
• 
Evidence of any other clinically significant uncontrolled condition(s)  
• 
If female, the patient is pregnant or breast-feeding 
Study treatment 
and response 
assessment 
Daratumumab will be administered in combination with GDP during the induction 
phase and as single agent during the maintenance phase; treatment will be 
continued up to 24 cycles from start of D-GDP or will be discontinued in case of 
decision to consolidate D-GDP response with allogeneic stem cell transplant, 
disease progression, unacceptable toxicity, withdrawal of consent and/or the 
investigator determines that further therapy is not in the patient best interest 
(e.g., due to non-compliance, toxicity, etc.) 
Response will be evaluated according to the Lugano 2014 criteria. 
Assessments 
schedule  
Response evaluation will be performed during the induction phase after cycles 4 
and 6 (only for those patients who will receive 6 D-GDP) from the beginning of 
treatment; during the maintenance phase response evaluation will be performed 
every 3 cycles up to cycle 12, every 4 cycles from cycle 13 to 24. 
Centralized 
analyses 
 
TEST 
APPENDIX REF 
REQUIRED QUANTITY 
Diagnosis review 
and CD38 
expression 
evaluation 
Appendix E 
YES 
1 BLOCK or 20 
UNSTAINED 
SLIDES 
Upfront centralized diagnosis review and evaluation of immunohistochemical 
positivity of CD38 will be performed during the screening phase in the relapse 
biopsy, or in the more recent biopsy in the case of refractory patients: this 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 15 of 79 
procedure is compulsory for treatment start, but the local pathology report is 
enough to enroll patient. Only patients with a confirmed diagnosis of PTCL-NOS, 
AITL or nodal lymphomas of TFH cell origin and a percentage of CD38 positive 
tumor cells ≥ 5% will be considered eligible to study protocol treatment. 
Statistical 
considerations 
It is expected for the current trial that D-GDP will improve the CR rate to 40% 
with an absolute improvement of 20%, while the toxicity rate is maintained at 
30%. 
Sample size: 
A'Hern's Single-Stage Phase II design will be used. The study sample size has 
been calculated according to the primary efficacy endpoint. 
Based on data from the literature, the null hypothesis that the true proportion of 
CR after four courses of D-GDP is 0.20 will be tested against an alternative CR 
proportion of 0.40 with an absolute improvement of 0.20, considered clinically 
promising with the experimental treatment.  
Assuming a type I error rate of 5% and a power of 80% when the CR proportion 
is 40% overall 35 patients will be accrued. The null hypothesis will be rejected if 
12 or more CR out of 35 patients are observed after four courses of D-GDP. 
Safety monitoring and stopping rules: 
In order to monitor the safety and the activity of the treatment in small cohorts of 
patients, we will use the Bayesian approach of Thall et al. (1995), as extended 
by Thall and Sung (1998).  
Monitoring of relevant toxicity after 4 cycles of D-GDP will be done to ensure 
that it is not higher than an acceptable toxicity of 30% (as defined in the safety 
endpoints) and the monitoring of activity after 4 cycles of D-GDP will be done 
to ensure that CR proportion is not lower than 40%.  
The prior probability of toxicity and activity are modeled by beta distributions 
[Beta (0.6,1.4) and Beta (0.8,1.2), respectively].  
We will stop the enrolment if the posterior probability of the treatment being more 
toxic or less active than expected is greater than 95%. 
Patients will be monitored according to the following stopping boundaries in 
cohorts of five patients: 
Number of 
patients 
enrolled 
Stop the enrollment if the 
cumulative relevant 
toxicities after 4 cycles are 
greater or equal to: 
Stop the enrollment if the 
number of cumulative CR 
after 4 cycles are lower or 
equal to: 
5 
4 
- 
10 
6 
1 
15 
9 
2 
20 
11 
4 
25 
13 
5 
30 
15 
7 
35 
17 
8 
 
The primary efficacy analysis will be performed after enrolment of 35 patients. 
The primary efficacy analysis will consist of an estimate of CRR on the efficacy 
population after 4 cycles of D-GDP therapy, with 90% confidence intervals 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 16 of 79 
(according to 1-sided alpha error of 0.05). To conclude that the new treatment is 
promising, the minimum number of patients with a CR is 12/35.  
The time-to-event functions (OS and PFS) will be estimated by the Kaplan-Meier 
product-limit method. 
Subgroup analyses on primary efficacy parameter (CRR) will be performed to 
assess the role of daratumumab maintenance and to explore potential 
prognostic role of CD38 expression. A logistic regression model will be used and 
the effect (CRR) and its 95%CI will be presented.  
For safety analysis, both at patient level and at therapy cycle level, summaries 
of incidence rates (frequencies and percentages) and intensity of individual 
adverse events by CTCAE v. 5.0 will be reported. 
The results of this study will support the rationale of a phase III randomized trial 
if both efficacy and safety endpoints will be considered promising. 
 
 
 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 17 of 79 
 
LIST OF ABBREVIATIONS AND GLOSSARY OF TERMS 
ABBREVIATION 
TERM 
AE 
Adverse Event 
AITL 
Angioimmunoblastic T cell lymphoma 
ALC 
Absolute Lymphocyte Count 
ALCL 
Anaplastic Large Cell Lymphoma 
ALT  
Alanine Transaminase  
ANC 
Absolute neutrophil count 
AST 
Aspartate Transaminase  
BSA 
Body Surface Area 
CNS 
Central Nervous System 
CR 
Complete Response 
CrCl 
Creatinine Clearance 
CRF 
Case Report Form 
CT 
Computed Tomography  
CTCAE 
Common Terminology Criteria for Adverse Events 
CTCL 
Cutaneous T-cell Lymphoma 
D 
Daratumumab 
DNA 
Deoxyribonucleic acid 
DoR 
Duration of Remission 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
EOR 
End of treatment Response 
ESR 
Erythrocyte Sedimentation Rate 
FIL 
Fondazione Italiana Linfomi 
FPFV 
First Patient First Visit  
GCP 
Good Clinical Practice 
GDP 
Gemcitabine, Dexamethasone, Cisplatin 
HBV 
Hepatitis B Virus 
HCV 
Hepatitis C Virus 
HIV 
Human Immunodeficiency Virus 
ICH 
Immunohistochemical 
IP 
Investigational Product 
LDH 
Lactic Dehydrogenase 
LPFV 
Last patient Fist Visit 
LPLV 
Last patient Last Visit 
LVEF 
Left Ventricular Ejection Fraction 
MF 
Mycosis Fungoides 
MRI 
Magnetic Resonance Imaging 
NHL 
Non-Hodgkin’s Lymphoma 
ORR 
Overall Response Rate 
OS 
Overall Survival 
PD 
Progressive Disease 
PET 
18F-FDG Positron Emission Tomography 
PFS 
Progression Free Survival 
PR 
Partial Response 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019 
 
Page 18 of 79 
ABBREVIATION 
TERM 
PS 
Performance Status 
PTCL 
Peripheral T Cell Lymphoma 
PTCL-NOS 
PTCL-not otherwise specified 
R/R 
Relapse or Refractory 
SAE 
Serious Adverse Event 
SD 
Stable Disease 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
TFH 
T-cell lymphomas of T-follicular helper origin 
TLS 
Tumor Lysis Syndrome 
TTR 
Time To Response 
ULN 
Upper Limit of Normal 
WOCBP 
Women of childbearing potential  
 
 
 

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 19 of 79 
 
 
STUDY FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Responsive Pts (CR, PR), if eligible, will be addressed to allo-SCT after cycle 4/6 
b After cycle 4, Pts in PR not eligible to allo-SCT or in SD can receive 2 additional cycles of D-GPD or be addressed directly to maintenance  

MD01-02_I01_PRDS00 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 20 of 79 
 
BACKGROUND 
 
OVERVIEW OF PERIPHERAL T-CELL LYMPHOMAS 
Peripheral T-cell lymphomas (PTCLs) are rare aggressive lymphomas, accounting for 5-10% of all non-
Hodgkin’s lymphomas in western countries. They arise from the proliferation of mature post-thymic 
lymphocytes and comprise different histologic subtypes among whom the most frequent in western 
countries are: peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-
cell lymphoma (AITL) and other nodal T-cell lymphomas of T-follicular helper origin (TFH), anaplastic large 
cell lymphoma (ALCL) ALK-positive (ALCL-ALK+) and ALK-negative (ALCL-ALK-) [1]. These different 
histologic subtypes, with the exception of ALCL-ALK+, share an aggressive clinical behavior and a poor 
prognosis. Response to induction chemotherapy is often inadequate and/or short-living. Nearly 50% of 
patients relapse or progress within one year from first-line therapy (CHOP or CHOEP). High-dose 
chemotherapy followed by autologous stem cell rescue is an option for younger patients, but many of them 
eventually relapse after transplant. The prognosis of relapsed refractory (R/R) patients is dismal, with an 
expected survival of less than one year. There is no standard of care in R/R patients [2, 3]. Gemcitabine-
based regimens are frequently used in R/R patients, with overall response rate (ORR) ranging from 30 to 
70% and a median progression-free survival (PFS) ranging from 4 to 11 months [4–6]. During the last few 
years, many efforts have been made to find new agents and therapeutic approaches for PTCLs. 
Unfortunately, with the exception of brentuximab-vedotin that showed remarkable activity in cutaneous T-
cell lymphomas and ALCLs [7, 8], the results achieved with other agents are much less impressive. The 
two HDAC inhibitors romidepsin and belinostat as well as the antimetabolite pralatrexate, approved by 
FDA for the treatment of R/R PTCLs, showed nearly 30% ORR with median PFS of only few months [9–
12]. 
Recent advances in the understanding the biology of PTCLs have been made, leading to the identification 
of BCL2, CD38 and PD-1 as potential therapeutic targets. A recent FIL study found that CD38 is expressed 
in 20/25 of AITL (80%) with variable scores; in particular 12 of the 24 positive cases (50%) resulted to be 
score 3 (percentage of positive tumor cells 50-75%) or 4 (percentage of positive tumor cells >75%). Fifty-
seven % of PTCLs-NOS were CD38 positive, also in this case with variable numbers of stained tumor cells 
and a level of score 3-4 positivity that overall appeared to be less than that of AITL (7/20, 35%). The 
probability of CD38 positivity in ALCLs was on the contrary very low, resulting 6/36 (17%) and 0/10 of 
evaluable cases of ALK- and ALK+ ALCLs, respectively [13]. 
 
CURRENT THERAPIES FOR RELAPSED REFRACTORY PTCLS  
Several novel agents have been evaluated in single-arm phase I and II studies in patients with 
relapsed/refractory disease including: immunoconjugates, immunotherapies, and immunomodulators; 
histone deacetylase (HDAC) inhibitors; antifolates; fusion proteins and nucleoside analogs. The efficacy 
of these agents is reported in the Table 1 below (adapted from a review by Coiffier et al [3]). 
 
Table 1. Current therapies for R/R PTCLs 
 
Drug/regimen 
N. of 
patients 
Type of patients 
ORR% 
Median DoR 
(months) 
Median PFS 
(months) 
Alemtuzumab 
14 
PTCL 
36 
NR 
NR 
10 
PTCL-NOS and MF 
60 
7 
NR 
Alisertib 
48 
NHL (including PTCL) 
27 
NR 
NR 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 21 of 79 
 
Table 1. (cont.) 
Belinostat 
120 
PTCL 
26 
8.3 
NR 
Bendamustine 
60 
PTCL and CTCL 
50 
3.5 
3.6 
Bortezomib 
12 
PTCL and CTCL 
67 
NR 
NR 
Denileukin 
diftitox 
27 
PTCL 
48 
NR 
6 
Gemcitabine 
13 
PTCL NOS and MF 
69 
NR 
NR 
10 
PTCL NOS and CTCL 
60 
13.5 
NR 
39 
PTCL-NOS and MF 
51 
NR 
NR 
Lenalidomide 
23 
PTCL 
30 
NR 
3.2 
10 
PTCL NOS 
30 
NR 
NR 
Mogamulizumab 
37 
CCR4+ PTCL/CTCL 
35 
NR 
3.0 
Pentostatin 
37 
NHL (including PTCL) 
13 
8 
NR 
44 
T-cell 
leukemias/lymphomas 
55 
4.3 
2.1 
14 
T-cell NHL 
50 
NR 
6 
Plitidepsin 
29 
PTCL 
21 
2.2 
1.6 
Pralatrexate 
29 
T-cell NHL 
54 
NR 
NR 
109 
PTCL 
29 
10.1 
3.5 
Romidepsin 
45 
PTCL and CTCL 
38 
8.9 
NR 
130 
PTCL 
25 
28 
4 
Tipifarnib 
93 
NHL (including PTCL) 
20 (50 in PTCL 
NOS) 
7.5 
NR 
Zanolizumab 
21 
PTCL 
24 
NR 
NR 
 
 
 
STUDY DRUG BACKGROUND: DARATUMUMAB 
 Mechanism of action 
CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including 
multiple myeloma and other hematopoietic cell types and tissues [14, 15] and has multiple functions, such 
as receptor mediated adhesion, signaling, and modulation of cyclase and hydrolase activity. Daratumumab 
is an IgG1κ human monoclonal antibody that binds CD38-expressing malignant cells with high affinity and 
has direct and indirect antitumor activity and diverse mechanisms of action, including: induction of 
apoptosis; immune-mediated actions, including complement-dependent cytotoxicity (CDC), antibody-
dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP); and 
immunomodulatory functions that target and deplete CD38-positive regulator immune suppressor cells, 
which leads to T-cell expansion and activation in patients who have a response  [16–20]. 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 22 of 79 
 
 
PRECLINICAL STUDIES 
 Pharmacodynamics 
Daratumumab has been shown to potently inhibit the in vivo growth of CD38-expressing tumor cells. Based 
on in vitro studies, daratumumab may utilize multiple effector functions, resulting in immune mediated 
tumor cell death. These studies suggest that daratumumab can induce tumor cell lysis through 
complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-
dependent cellular phagocytosis in malignancies expressing CD38. A subset of myeloid derived 
suppressor cells (CD38+MDSCs), regulatory T cells (CD38+Tregs) and B cells (CD38+Bregs) are 
decreased by daratumumab mediated cell lysis. T cells (CD3+, CD4+, and CD8+) are also known to 
express CD38 depending on the stage of development and the level of activation. Significant increases in 
CD4+ and CD8+ T cell absolute counts, and percentages of lymphocytes, were observed with 
daratumumab treatment in peripheral whole blood and bone marrow. In addition, T-cell receptor DNA 
sequencing verified that T-cell clonality was increased with daratumumab treatment, indicating immune 
modulatory effects that may contribute to clinical response. 
Daratumumab induced apoptosis in vitro after Fc mediated cross-linking. In addition, daratumumab 
modulated CD38 enzymatic activity, inhibiting the cyclase enzyme activity and stimulating the hydrolase 
activity. The significance of these in vitro effects in a clinical setting, and the implications on tumor growth, 
are not well-understood. 
A recent preclinical experience with daratumumab in a large panel of T-ALL patient-derived xenografts 
(PDX) [21]demonstrated striking efficacy of the drug in 14/15 different PDX. These results demonstrated 
that CD38 is a novel target with broad potential, and daratumumab is a promising novel therapy in the 
treatment of T-ALL. 
 Non-clinical toxicology: Carcinogenesis, Mutagenesis, Impairment of Fertility 
No carcinogenicity or genotoxicity studies have been conducted with daratumumab. No animal studies 
have been performed to evaluate the potential effects of daratumumab on reproduction or development, 
or to determine potential effects on fertility in males or females 
 Animal Toxicology 
Toxicology data have been derived from studies with daratumumab in chimpanzees and with a surrogate 
anti-CD38 antibody in cynomolgus monkeys. No chronic toxicity testing has been conducted. 
 
CLINICAL PHARMACOLOGY 
 Pharmacodynamics 
NK cells express CD38 and are susceptible to daratumumab mediated cell lysis. Decreases in absolute 
counts and percentages of total NK cells (CD16+CD56+) and activated (CD16+CD56dim) NK cells in 
peripheral whole blood and bone marrow were observed with daratumumab treatment. 
 Pharmacokinetics 
Over the dose range from 1 to 24 mg/kg as monotherapy or 1 to 16 mg/kg of DARZALEX® in combination 
with other treatments, increases in area under the concentration-time curve (AUC) were more than dose-
proportional. 
Following the recommended dose of 16 mg/kg when daratumumab was administered as monotherapy or 
in combination therapy, the mean serum maximal concentration (Cmax) value at the end of weekly dosing, 
was approximately 2.7 to 3-fold higher compared to the mean serum Cmax following the first dose. The 
mean ± standard deviation (SD) trough serum concentration (Cmin) at the end of weekly dosing was 573 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 23 of 79 
 
± 332 μg/mL when daratumumab was administered as monotherapy and 502 ± 196 to 607 ± 231 μg/mL 
when daratumumab was administered as combination therapy. When daratumumab was administered as 
monotherapy, daratumumab steady state was achieved approximately 5 months into the every 4-week 
dosing period (by the 21st infusion), and the mean ± SD ratio of Cmax at steady-state to Cmax after the 
first dose was 1.6 ± 0.5. 
7.5.2.1. 
Distribution 
At the recommended dose of 16 mg/kg, the mean ± SD central volume of distribution was 4.7 ± 1.3 L when 
daratumumab was administered as monotherapy and 4.4 ± 1.5 L when daratumumab was administered 
as combination therapy. 
7.5.2.2. 
Elimination 
Daratumumab clearance decreased with increasing dose and with multiple dosing. At the recommended 
dose of 16 mg/kg of daratumumab as monotherapy, the mean ± SD linear clearance was estimated to be 
171.4 ± 95.3 mL/day. The mean ± SD estimated terminal half-life associated with linear clearance was 18 
± 9 days when daratumumab administered as monotherapy and a mean of 22-23 days when daratumumab 
was administered as combination therapy. 
7.5.2.3. 
Special populations 
The following population characteristics have no clinically meaningful effect on the pharmacokinetics of 
daratumumab in patients administered with drug as monotherapy or as combination therapy: sex, age (31 
to 93 years), mild [total bilirubin 1 to 1.5 times upper limit of normal (ULN) or aspartate aminotransaminase 
(AST)>ULN] and moderate (total bilirubin 1.5 to 3 times ULN and any AST) hepatic impairment, or renal 
impairment [Creatinine clearance (CrCl) 15 -89 mL/min]. The effect of severe (total bilirubin >3 times ULN 
and any AST) hepatic impairment is unknown. Increasing body weight increased the central volume of 
distribution and clearance of daratumumab, supporting the body weight-based dosing regimen. 
7.5.2.4. 
Drug Interactions 
Effect of Other Drugs on Daratumumab 
The coadministration of lenalidomide, pomalidomide or bortezomib with daratumumab did not affect the 
pharmacokinetics of daratumumab. 
Effect of Daratumumab on Other Drugs 
The coadministration of daratumumab with bortezomib or pomalidomide did not affect the 
pharmacokinetics of bortezomib or pomalidomide. 
 
CLINICAL TRIALS 
 Relapsed/Refractory Multiple Myeloma  
Two trials scheduling the administration of daratumumab monotherapy were conducted on 
relapsed/refractory heavily pretreated multiple myeloma (MM) patients, both showing encouraging efficacy 
with a favorable safety profile in this population of patients. 
The SIRIUS trial evaluated daratumumab monotherapy at a dosage of 16 mg/Kg per week for 8 weeks 
(cycles 1 and 2), then every 2 weeks for 16 weeks (cycles 3-6), and then every 4 weeks thereafter (cycle 
7 and higher, until unacceptable toxicity or disease progression) in a cohort of 106 multiple myeloma 
patients who were previously treated with at least three lines of therapy (including proteasome inhibitors 
and immunomodulatory drugs), or were refractory to both proteasome inhibitors and immunomodulatory 
drugs [22]. Patients had received a median of 5 prior lines of therapy, and 85 (80%) patients had previously 
received autologous stem cell transplantation (ASCT). Overall response rate (partial response [PR] + very 
good PR [VGPR]+ complete response [CR] + stringent CR [sCR]) was recorded in 31 (29.2%) of patients 
(sCR: 3, 2.8%; CR:0; VGPR: 10, 9.4%; PR: 18, 17.0%).  
The study GEN501 population consisted of relapsed or refractory MM patients who had received at least 
2 different prior cytoreductive therapies [23]. Forty-two patients received 16 mg/Kg once weekly (8 doses), 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 24 of 79 
 
twice monthly (8 doses), and monthly for up to 24 months, or until unacceptable toxicity or disease 
progression). Patients had received a median of 5 prior lines of therapy, in 74% of them including ASCT. 
The overall response rate was 36%: 15 patients had a partial response or better, including 2 with a 
complete response and 2 with a very good partial response). The median progression-free survival was 
5.6 months (95% confidence interval [CI], 4.2 to 8.1), and 65% (95% CI, 28 to 86) of the patients who had 
a response did not have progression at 12 months. The median duration of response was not estimable 
(range: 2.2 to 13.1+ months). 
Two phase III randomized trials comparing two different background therapies +/- daratumumab were 
conducted almost contemporaneously and published in 2016. 
The POLLUX phase III trial compared treatment with daratumumab 16 mg/kg in combination with 
lenalidomide (25 mg once daily orally on Days 1-21 of repeated 28-day cycles) and low-dose 
dexamethasone (oral or intravenous dexamethasone 40 mg/week) (DRd) to treatment with lenalidomide 
and low-dose dexamethasone (Rd) at the same doses in patients with multiple myeloma who had received 
at least one prior therapy [24]. Treatment was continued in both arms until disease progression or 
unacceptable toxicity. A total of 569 patients were randomized; 286 to the DRd arm and 283 to the Rd 
arm. Patients had received a median of 1 prior line of therapy. Sixty-three percent (63%) of patients had 
received prior ASCT. The majority of patients (86%) received a prior proteasome inhibitor, 55% of patients 
had received a prior immunomodulatory agent, including 18% of patients who had received prior 
lenalidomide; and 44% of patients had received both a prior proteasome inhibitor and immunomodulatory 
agent. Overall response rate (partial response [PR] + very good PR [VGPR]+ complete response 
[CR] + stringent CR [sCR]) was 91.3% and 74.6% in the DRd and Rd arm, respectively (P<0.0001), with 
sCR, CR, VGPR and PR of 17.8%, 24.5%, 32.2%, 16.8% and 7.1%, 11.7%, 24.4%, 31.4% in DRd and Rd 
arm, respectively. POLLUX demonstrated an improvement in PFS in the DRd arm as compared to the Rd 
arm; the median PFS had not been reached in the DRd arm and was 18.4 months in the Rd arm (hazard 
ratio [HR]=0.37; 95% CI: 0.27, 0.52; p<0.0001), representing 63% reduction in the risk of disease 
progression or death in patients treated with DRd. The median duration of response had not been reached 
in the DRd group (range: 1+ to 19.8+ months) and was 17.4 months (range: 1.4 to 18.5+ months) in the 
Rd group. With a median follow-up of 13.5 months, 75 deaths were observed; 30 in the DRd group and 45 
in the Rd group [24]. 
The CASTOR phase III trial compared treatment with daratumumab 16 mg/kg in combination with 
bortezomib and dexamethasone (DVd), to treatment with bortezomib and dexamethasone (Vd) in patients 
with multiple myeloma who had received at least one prior therapy [25]. Bortezomib was administered by 
SC injection or IV infusion at a dose of 1.3 mg/m
2 body surface area twice weekly for two weeks (Days 1, 
4, 8, and 11) of repeated 21-day treatment cycles, for a total of 8 cycles. Dexamethasone was administered 
orally at a dose of 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each of the 8 bortezomib cycles (80 
mg/week for two out of three weeks of the bortezomib cycle). Bortezomib and dexamethasone were given 
for 8 three-week cycles in both treatment arms; whereas daratumumab was given until disease 
progression. A total of 498 patients were randomized; 251 to the DVd arm and 247 to the Vd arm. Patients 
had received a median of 2 prior lines of therapy and 61% of patients had received prior ASCT. Sixty-nine 
percent (69%) of patients had received a prior proteasome inhibitor (66% received bortezomib) and 76% 
of patients received an immunomodulatory agent (42% received lenalidomide). Overall response rate 
(partial response [PR] + very good PR [VGPR]+ complete response [CR] + stringent CR [sCR]) was 
79.3% and 59.9% in the DVd and Vd arm, respectively (P<0.0001), with sCR, CR, VGPR and PR of 4.4%, 
13.9%, 38.2%, 22.7% and 2.0%, 6.5%, 19.0%, 32.4% in DVd and Vd arm, respectively. CASTOR 
demonstrated an improvement in PFS in the DVd arm as compared to the Vd arm; the median PFS had 
not been reached in the DVd arm and was 7.2 months in the Vd arm (HR [95% CI]: 0.39 [0.28, 0.53]; p-

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 25 of 79 
 
value < 0.0001), representing a 61% reduction in the risk of disease progression or death for patients 
treated with DVd versus Vd. The median duration of response had not been reached in the DVd group 
(range: 1.4+ to 14.1+ months) and was 7.9 months (1.4+ to 12+ months) in the Vd group. With a median 
follow-up of 7.4 months, 65 deaths were observed; 29 in the DVd group and 36 in the Vd group were 
observed [25].  
Finally, EQUULEUS was an open-label trial in which 103 patients with multiple myeloma who had received 
a prior proteasome inhibitor and an immunomodulatory agent, received 16 mg/kg daratumumab in 
combination with pomalidomide and low-dose dexamethasone until disease progression [26]. 
Pomalidomide (4 mg once daily orally on Days 1-21 of repeated 28-day cycles) was given with low dose 
oral or intravenous dexamethasone 40 mg/ week. Patients in the study had received a median of 4 prior 
lines of therapy. Seventy-four percent (74%) of patients had received prior ASCT. Ninety-eight percent 
(98%) of patients received prior bortezomib treatment, and 33% of patients received prior carfilzomib. All 
patients received prior lenalidomide treatment, with 98% of patients previously treated with the 
combination of bortezomib and lenalidomide. Efficacy results shown an overall response rate of 59.2%: 
sCR: 7.8%; CR:5.8%; VGPR: 28.2%; PR: 17.5%). The median duration of response was 13.6 months 
(range: 0.9+ to 14.6+ months). 
 Newly Diagnosed Multiple Myeloma 
Few months ago, the results of the first trial testing daratumumab for the front-line treatment of MM was 
published. The phase III study ALCYONE compared treatment with daratumumab 16 mg/kg in combination 
with bortezomib, melphalan and prednisone (D-VMP), to treatment with VMP in patients with newly 
diagnosed multiple myeloma [27]. Bortezomib was administered by subcutaneous (SC) injection at a dose 
of 1.3 mg/m2 body surface area twice weekly at Weeks 1, 2, 4 and 5 for the first 6-week cycle (Cycle 1; 8 
doses), followed by once weekly administrations at Weeks 1, 2, 4 and 5 for eight more 6-week cycles 
(Cycles 2-9; 4 doses per cycle). Melphalan at 9 mg/m2, and prednisone at 60 mg/m2 were orally 
administered on Days 1 to 4 of the nine 6-week cycles (Cycles 1-9). Daratumumab treatment was 
continued until disease progression or unacceptable toxicity. A total of 706 patients were randomized: 350 
to the D-VMP arm and 356 to the VMP arm. Overall response rate was 90.9% and 73.9% in the D-VMP 
and VMP arm, respectively (P<0.0001), with sCR, CR, VGPR and PR of 18.0%, 24.6%, 28.6%, 19.7% 
and 7.0%, 17.4%, 25.3%, 24.2% in D-VMP and VMP arm, respectively. The MRD negativity rate was also 
assed, resulting 22.3% in D-VMP and 6.2% in VMP arm, respectively (P<0.0001). ALCYONE 
demonstrated an improvement in PFS in the D-VMP arm as compared to the VMP arm; the median PFS 
had not been reached in the D-VMP arm and was 18.1 months (95% CI:16.53, 19.91) in the VMP arm 
(hazard ratio [HR]=0.5; 95% CI: 0.38, 0.65; p<0.0001), representing 50% reduction in the risk of disease 
progression or death in patients treated with D-VMP The median duration of response had not been 
reached in the D-VMP group and was 21.3 months (range: 0.5+, 23.7+) in the VMP group [27].  
 Clinical Activity in other hematological malignancies 
Expression of CD38 has been associated with a number of diseases. Most notably, CD38 is expressed in 
a large number of hematological malignancies. In addition to MM, consistent expression has been 
observed the malignant cells of CLL [28, 29], and was also reported in Waldenström’s macroglobulinemia 
[30], mantle cell lymphoma [31], acute lymphoblastic leukemia [32], acute myeloid leukemia [32, 33], NK 
cell leukemia [34] and NK/T-cell lymphoma [21, 35, 36].  
The expression of CD38 as a target-molecules has not been extensively investigated in PTCLs, limiting 
the possible use of targeted therapies in these lymphoid tumors. A study by Wang et al on 94 patients 
diagnosed with Extranodal NK/T-cell lymphoma (ENKTL) taken from the database of Sun Yat-sen 
University Cancer Center of China and treated with chemo/radiotherapy from Jan 2002 to Dec 2013, 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 26 of 79 
 
reported a strong CD38 expression in this subset of extranodal PTCL (47 patients, 50%), and 
demonstrated a poor prognosis for strong CD38 expressor patients (Progression-free survival: HR=2.535 
with 95%CI:1.258–5.109, P= 0.009), thus indicating the potential role of CD38 as a therapy target [35]. 
Hari and coworkers [36] published a case report of a 56-year old woman with stage IE nasal-type ENKTL 
at diagnosis who was heavily pretreated (5 lines, including allo-SCT) due to extensive relapsed, refractory 
disease and who then received off-label therapy with daratumumab at a dose of 16 mg/Kg/week achieving 
a CR after 6 weeks of treatment, reconfirmed at 21 weeks of follow-up. 
A recent FIL study [13] found that CD38 is expressed in 20/25 of AITL (80%) with variable scores; in 
particular 7 of the 20 positive cases (35%) resulted to be score 3 (percentage of positive tumor cells 50-
75%) or 4 (percentage of positive tumor cells >75%). Fifty-seven % of PTCL-NOS were CD38 positive, 
also in this case with variable numbers of stained tumor cells and a level of score 3-4 positivity of 12/24 
(50%). The probability of CD38 positivity in ALCLs was on the contrary very low, resulting 6/36 (17%) and 
0/10 of evaluable cases of ALK- and ALK+ ALCLs, respectively [13]. Actually, 9 cases classified by the 
study as PTCL-NOS according to the WHO 2008, would have been identified as nodal T-cell lymphomas 
with TFH phenotype according to the WHO 2016, indicating that also these entities express CD38. 
 
STUDY RATIONALE 
Patients with relapsed/refractory PTCLs have a dismal prognosis. With available treatments, responses 
are short-living and overall survival is usually less than one year. New treatment options are therefore 
urgently needed. Recent insights into the biology of PTCLs have provided the basis for the use of targeted 
therapies in this setting. In particular, the discovery that CD38 is over-expressed in the majority of patients 
with PTCL-NOS, AITL and nodal lymphomas of TFH origin makes CD38 a suitable therapeutic target.  
Aim of this study is to evaluate if the addition of Daratumumab to an induction Gemcitabine-
Dexamethasone-Cisplatin regimen (GDP) followed by a maintenance therapy with Daratumumab could 
represent a novel salvage treatment for patients with R/R CD38 positive PTCL-NOS, AITL and nodal 
lymphoma of TFH origin. 
 
The rationale of this study is based on: 
• 
the activity daratumumab has been demonstrated in multiple myeloma and, occasionally, in some 
other hematological disorders including T-cell neoplasia [21, 36] 
• 
the safety profile of daratumumab is good 
• 
daratumumab has been safely and effectively combined with other cytotoxic agents in multiple 
myeloma 
• 
CD38 is expressed in a significant proportion of PTCL-NOS, AITL and nodal lymphomas of TFH 
origin 
• 
the good results observed in previous studies in NHL when a monoclonal antibody was combined 
to standard chemotherapy 
• 
the choice of GDP was made because this regimen has been extensively adopted as salvage 
therapy for R/R PTCL [6, 37–48] and therefore the results of this study will be compared to historical 
GDP controls. 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 27 of 79 
 
 
STUDY OBJECTIVES 
 
PRIMARY OBJECTIVE 
The primary objective of the study is to evaluate the efficacy of 4 courses of D-GDP in terms of complete 
response in PTCL-NOS, AILT and TFH phenotype patients, refractory and/or relapsed after at least one 
and a maximum of two lines of previous therapy (autologous stem cell transplant performed as part of 
consolidation to a previous line of therapy should not be considered as a line of therapy). 
 
SECONDARY OBJECTIVES 
• 
To evaluate the Overall Response Rate (ORR); 
• 
To evaluate the efficacy in terms of Overall survival (OS); 
• 
To evaluate the efficacy in terms of Progression-free survival (PFS); 
• 
To evaluate the safety of D-GDP. 
 
EXPLORATIVE OBJECTIVES 
• 
To assess the role of daratumumab maintenance; 
• 
To evaluate the correlation between intensity of CD38 expression and response.  
 
STUDY DESIGN  
 
OVERVIEW OF STUDY DESIGN 
This is an open-label, multicenter, single arm, single-stage phase II trial in patients aged 18-75 years, with 
refractory/relapsed CD38 positive PTCL-NOS, AITL and other nodal lymphomas of TFH cell origin. 
During the screening (within 4 weeks before treatment start) the central diagnosis review and evaluation 
of CD38 expression are to be done in concomitance with other planned procedures. The patient will be 
asked to give his/her consent prior to centralize the material collected and used for local diagnosis of 
refractory/relapsed PTCL-NOS, AITL or TFH lymphoma to the FIL central designated laboratory.  
The material that will be used for central diagnosis confirmation and evaluation in immunohistochemistry 
of CD38 expression is that coming from the relapse biopsy or from the more recent biopsy in the case of 
refractory patients: this is a preclusive procedure to confirm patients are eligible to receive the experimental 
treatment including daratumumab (see Appendix E for details).  
Only patients with confirmed diagnosis of PTCL-NOS, AITL or TFH lymphoma and a percentage of CD38 
positive tumor cells ≥ 5% will be included onto the study. A core needle biopsy is considered sufficient for 
central evaluations. Tests at central laboratory can be carried out  in bone marrow sections in those 
patients with only bone marrow lymphoma infiltration. 
The treatment phase consists of an induction phase and a maintenance phase.  
After 4 courses of D-GDP, patients in CR/PR eligible for allo-SCT will be addressed to allo-SCT 
consolidation.  
Otherwise, patients in CR will enter the maintenance phase at this point of the study.  
Patients in PR (not eligible for allo-SCT) or in SD after D-GDP x 4 can receive 2 additional courses of D-
GDP before maintenance or can move directly to maintenance, according to center choice (based on 
patient condition, performance status and quality of response).  
Patients who respond (CR, PR) after 6 courses of induction phase (end of induction, EOI) and eligible to 
allo-SCT will be addressed to allo-SCT consolidation.  
Patients in PD at any time will discontinue treatment, as well as patients experiencing at any time 
unacceptable toxicity.  

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 28 of 79 
 
 
Procedures to be performed during the study are summarized on schedule of assessment (see Chapter 
15, “Study procedures timepoints”). 
 
NUMBER OF PATIENTS 
A total of 35 patients satisfying the inclusion criteria will be enrolled in the study, will receive the 
experimental treatment and will be evaluated for the study endpoints. Patients that after the screening will 
have no confirmation of diagnosis of PTCL-NOS, AITL or TFH phenotype, and those with CD38 expression 
< 5% will be considered screening failures.   
 
DURATION OF THE STUDY 
Patients will be recruited over 18 months.  
The median expected duration of the treatment period is approximately: 6 months on an average (for 
induction + maintenance). Last patient followed for final analysis: 24 months from the start of treatment. 
End of study is defined by the last visit planned by the protocol 24 months after the start of treatment of 
the last patient (LPLV), that means approximately 42 months (3.5 years) after the study start.   
The Final Study Report will be provided after the end of the Study. 
 
STUDY POPULATION 
 
INCLUSION CRITERIA 
• 
Histologically documented diagnosis of CD38 positive PTCL-NOS, AITL, and other nodal 
lymphomas of TFH cell origin as defined in the 2017 edition of the World Health Organization 
(WHO) classification [1]. Only patients with percentage of CD38 positive tumor cells ≥ 5% in the 
relapse biopsy or in the more recent biopsy in the case of refractory patients will be included onto 
the study (a core needle biopsy is considered sufficient for CD38 evaluation); CD38 can be 
evaluated in bone marrow sections in those patients with bone marrow lymphoma infiltration 
• 
Age 18-75 years 
• 
Relapsed or refractory to at least one and a maximum of two previous lines of treatment 
• 
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 
• 
At least one site of measurable nodal disease at baseline ≥ 2.0 cm in the longest transverse 
diameter as determined by CT scan (MRI is allowed only if CT scan cannot be performed). Note: 
Patients with only bone marrow involvement are eligible 
• 
Adequate hematological counts defined as follows: 
- Absolute Neutrophil count (ANC) > 1.0 x 109/L unless due to bone marrow involvement by 
lymphoma 
- Platelet count ≥ 50.000/mm3 unless due to bone marrow involvement by lymphoma 
• 
Adequate renal function defined as follows: 
- Creatinine clearance ≥ 40 mL/min (Cockcroft–Gault formula) 
• 
Adequate hepatic function per local laboratory reference range as follows: 
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN  
- Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert’s syndrome or of non-hepatic 
origin)  
• 
Subject understands and voluntarily signs an informed consent form approved by an Independent 
Ethics Committee (IEC), prior to the initiation of any screening or study-specific procedures 
• 
Subject must be able to adhere to the study visit schedule and other protocol requirements 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 29 of 79 
 
• 
Life expectancy ≥ 3 months 
• 
Women must be: 
- postmenopausal for at least 1 year (must not have had a natural menses for at least 12 
months) 
- surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or 
otherwise be incapable of pregnancy), 
- completely abstinent (periodic abstinence from intercourse is not permitted) or if sexually 
active, be practicing two highly effective methods of birth control (e.g., prescription oral 
contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double 
barrier method (e.g.: condoms, diaphragm, or cervical cap, with spermicidal foam, cream, 
or gel, male partner sterilization) as local regulations permit, before entry, and must agree 
to continue to use the same method of contraception throughout the study. They must also 
be pre-pared to continue birth control measures for at least 3 months after terminating 
treatment. 
- Women of childbearing potential must have a negative pregnancy test at screening 
• 
Men must agree to use an acceptable method of contraception (fort them-selves or female partners 
as listed above) for the duration of the study. Men must agree to use a double barrier method of 
birth control and to not donate sperm during the study and for 3 months after receiving the last 
dose of study drug. 
• 
Male even if surgically sterilized (i.e., status post vasectomy) must agree to one of the following: 
- practice effective barrier contraception during the entire study treatment period and through 
3 months after the last dose of study drug, or 
- agree to practice true abstinence, when this is in line with the preferred and usual lifestyle 
of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation 
methods for the female partner] and withdrawal are not acceptable methods of 
contraception) 
 
EXCLUSION CRITERIA 
• 
Histological diagnosis different from CD38 positive PTCL-NOS, AITL, and other nodal lymphomas 
of TFH cell origin 
• 
More than two lines of previous treatment (autologous stem cell transplant performed as part of 
consolidation to a previous line of therapy should not be considered as a line of therapy) 
• 
Previous treatment with Gemcitabine or Platinum based regimens; patients who received a single 
course of Platinum based course (i.e. DHAP) are not excluded 
• 
Prior therapy with monoclonal antibody antiCD38 
• 
Concomitant experimental therapy 
• 
Relapse after allo-SCT 
• 
CNS involvement with lymphoma 
• 
Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, 
radiotherapy, investigational therapy, including targeted small molecule agents within 14 days prior 
to the first dose of study drug 
• 
Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment 
• 
Subject is: 
- 
Known to be seropositive for human immunodeficiency virus (HIV) 
- 
Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). 
Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 30 of 79 
 
antibodies to hepatitis B core antigen [anti-HBc] ± antibodies to hepatitis B surface antigen 
[anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement 
of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. 
EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs 
positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not 
need to be tested for HBV DNA by PCR. 
- 
Known to be seropositive for hepatitis C (except in the setting of a sustained virologic response 
[SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy). 
• 
Cardiovascular disease (NYHA class ≥2) 
• 
Creatinine Clearance < 40 mL/min (Cockcroft–Gault formula) 
• 
Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic 
disease that would preclude participation in the study or compromise ability to give informed 
consent 
• 
Any history of other active malignancies within 3 years prior to study entry, with the exception of 
adequately treated in situ carcinoma of the cervix uterine, basal cell carcinoma of the skin or 
localized squamous cell carcinoma of the skin, previous malignancy confined and surgically 
resected with curative intent 
• 
Uncontrolled and/or active systemic infection (viral, bacterial or fungal) 
• 
Evidence of any other clinically significant uncontrolled condition(s) 
• 
If female, the patient is pregnant or breast-feeding 
 
PATIENTS ENROLLMENT 
 
INFORMED CONSENT 
The Investigator(s) must obtain informed consent of a patient prior to any study related procedures as per 
Good Clinical Practices (GCP). 
Documentation that informed consent occurred prior to the patient’s entry into the study and of the informed 
consent process should be recorded in the patient’s source documents. Subjects will be informed that their 
participation is voluntary and that they may withdraw consent to participate at any time. They will be 
informed that choosing not to participate will not affect the care the subject will receive for the treatment of 
their disease. Subjects will be told that alternative treatments are available if they refuse to take part in the 
study and that such refusal will not prejudice future treatment. The subject will be given sufficient time to 
read the informed consent form and the opportunity to ask questions. After this explanation and before 
entry to the study, consent should be appropriately recorded by means of the subject's dated signature. 
After having obtained the consent, a copy of the informed consent form must be given to the subject.  
The original consent form signed and dated by the patient and by the person consenting the patient prior 
to the patient’s entry into the study must be maintained in the Investigator’s study files and a copy given 
to the patient. In addition, if a protocol is amended and it impacts on the content of the informed consent, 
the informed consent must be revised. Patients participating in the study when the amended protocol is 
implemented must be re-consented with the revised version of the informed consent. The revised consent 
form signed and dated by the patient and by the person consenting the patient must be maintained in the 
Investigator’s study files and a copy given to the patient. 
 
PATIENT REGISTRATION AND DATA COLLECTION 
Following local diagnosis of refractory/relapsed PTCL-NOS, AITL or TFH, check of inclusion/exclusion 
criteria and written informed consent signature, patients should be registered online at www.filinf.it, in the 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 31 of 79 
 
study dedicated section. An email of confirmation will be sent to the local investigator, to coordinating 
investigator of the study and to the FIL Trial office staff. If the patient is confirmed with a diagnosis eligible 
for the study and with CD38 tumor expression ≥ 5%, the information will be promptly provided to the local 
investigator and the protocol treatment can be started. All CRFs for patient’s registration and data 
collection could be reached in the restricted area of the FIL website by authorized users. 
 
TREATMENT 
 
TREATMENT SCHEDULE AND DESIGN 
 
Pre- and Post- infusion Medications 
Pre- and post- daratumumab infusion medications should be instituted as needed (see paragraph 13.3.1 
“Recommended concomitant medications”). 
 
Treatment during induction phase 
GDP will be prepared and administered according to the standard preparation and infusion procedures at 
each investigational site. 
Daratumumab (D): will be given intravenously (i.v.) at a dose of 8 mg/Kg on day 2 and 9 of cycle 1; from 
cycle 2 it will be given at a dose of 16 mg/Kg on day 2 and 9 of each cycle. 
 
Induction phase:  
4-6 courses (according to response after cycle 4 and patient compliance) of D-GDP every 21 days 
according to the following schedule: 
 
Cycle 1 
Q21 days 
Daratumumab 
8 mg/Kg i.v.  
days 2 and 9 
Gemcitabine 
1000 mg/m2, i.v. 
days 1 and 8 
Cisplatin 
75 mg/m2, i.v. 
day 1 
Dexamethasone 
40 mg/day, i.v. or po 
days 1-2-3-4-9 
Gemcitabine at day 8 skipped in case of grade 3-4 toxicity 
G-CSF support should be given from day 3 to 6, and from day 10 to 13 (to be prolonged if 
necessary). 
Cycles 2-4/6 
Q21 days 
Daratumumab 
16 mg/Kg i.v.  
days 2 and 9 
Gemcitabine 
1000 mg/m2, i.v. 
days 1 and 8 
Cisplatin 
75 mg/m2, i.v. 
day 1 
Dexamethasone 
40 mg/day, i.v. or po 
days 1-2-3-4-9 
Gemcitabine at day 8 skipped in case of grade 3-4 toxicity 
G-CSF support should be given from day 3 to 6, and from day 10 to 13 (to be prolonged if 
necessary). 
 
Patients in CR/PR after 4/6 cycles of D-GDP will be shift to allo-SCT, if eligible. Patients not eligible to 
transplant or achieving at least a SD after induction will receive maintenance. 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 32 of 79 
 
 
Treatment during maintenance phase 
Maintenance phase will start 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade > 1, 
after toxicity is resolved) and up to 24 cycles from start of D-GDP according to the following schedule:  
Maintenance schedule 
Q28 days 
Daratumumab 
16 mg/Kg i.v.  
single administration 
on day 1 
 
Treatment will be continued up to 24 cycles from start of D-GDP.  
 
Treatment discontinuation  
Treatment with D-GDP or daratumumab single agent will be discontinued in case of: 
• 
decision of the investigator to consolidate D-GDP response with allogeneic stem cell transplant 
• 
disease progression 
• 
unacceptable toxicity 
• 
withdrawal of consent 
• 
investigator determines that further therapy is not in the patient’s best interest (e.g., due to non-
compliance, toxicity, etc.) 
 
DARATUMUMAB 
 
Supplier  
DARZALEX® (daratumumab) will be supplied by Janssen as 100 mg (5 ml) or 400 mg (20 ml) vials (20 
mg/ml concentrate for solution for infusion to be diluted prior to administration). Study drug will be supplied 
by Janssen to the Sponsor for the entire period of the study. The Sponsor will be responsible for sending 
the drugs to all participating sites. Drugs will be delivered to sites only after having received the registration 
form and the drug request form, correctly filled and signed by the Investigator. 
 
Dosage form, packaging and labeling 
Daratumumab will be administered intravenously (i.v.) in combination with GDP (during the induction 
phase) or as a single agent (during the maintenance phase).  
 
Receipt of study drug 
The Sponsor is responsible for taking an inventory of each shipment of study drug received, and comparing 
it with the accompanying study drug accountability form. The Sponsor will verify the accuracy of the 
information on the form, sign and date it, retain a copy in the study file and return a copy to Janssen or its 
representative. 
 
Storage and handling 
At the study site, all investigational study drugs will be stored in a locked, safe area to prevent unauthorized 
access. The study drug should be stored in a refrigerator (2 °C-8 °C). Do not freeze. 
Store in the original package in order to protect from light. 
Storage conditions after dilution of the medicinal product: from a microbiological point of view, unless the 
method of opening/dilution precludes the risk of microbial contamination, the product should be used 
immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user 
and should be no more than 24 hours at refrigerated conditions (2 °C-8 °C) protected from light, followed 
by 15 hours (including infusion time) at room temperature (15°C - 25°C) and room light. 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 33 of 79 
 
 
Unused study drug supplies 
The sponsor will inform the investigators on the return or destruction of unused study drug. If any study 
drug is lost or damaged, its disposition should be documented in the source documents. Study drug 
supplies will be retained at the clinical site pending instructions for disposition by the sponsor. 
 
ADMITTED/EXCLUDED CONCOMITANT MEDICATION 
 
Recommended concomitant medications 
Steroids 
For patients with B symptoms, bulky disease, tumor circulating cells count > 20 x 109/L, or if judged of 
clinical benefit by the treating physician during the screening phase, it is allowed pre-treatment with 
Prednisone 0.25-0.5 mg/kg/d, to be suspended within the first month of therapy. If clinically indicated a 
single administration of Vincristine 1 mg before initiating treatment is admitted. 
Pre-infusion medication 
Pre-infusion medications should be administered to reduce the risk of IRRs to all patients 1-3 hours 
prior to every infusion of Daratumumab as follows. 
• Corticosteroids 
- 
during induction daratumumab is administered with GDP. Dexamethasone should be 
administered prior to every daratumumab infusion. Dexamethasone dose (40 mg) could be split 
to half before and half after daratumumab infusion. Dexamethasone is given intravenously prior 
to the first daratumumab infusion and oral administration may be considered prior to subsequent 
infusions. 
- 
During 
daratumumab 
monotherapy 
maintenance, 
long-acting 
or 
intermediate-acting 
corticosteroids administration is recommended: methylprednisolone 100 mg, or equivalent, 
administered intravenously before daratumumab. Following the second infusion, the dose of 
corticosteroid may be reduced (oral or intravenous methylprednisolone 60 mg); 
• Antipyretics (oral paracetamol 650 to 1,000 mg); 
• Antihistamine (oral or intravenous diphenhydramine 25 to 50 mg or equivalent). 
Post-infusion medications 
Post-infusion corticosteroids medication should be administered to reduce the risk of delayed infusion-
related reactions. 
When daratumumab is administered in monotherapy, oral corticosteroid (20 mg methylprednisolone or 
equivalent dose of an intermediate-acting or long-acting corticosteroid in accordance with local standards) 
should be administered on each of the two days following all infusions (beginning the day after the 
infusion). 
Since during induction the background regimen contains dexamethasone, if the steroid is administered the 
day after the daratumumab infusion, additional post-infusion medications may not be needed. If not, 
administering low-dose oral methylprednisolone (≤ 20 mg) or equivalent the day after daratumumab 
infusion may be considered.  
Additionally, for patients with a history of chronic obstructive pulmonary disease, the use of post-infusion 
medications including short and long acting bronchodilators, and inhaled corticosteroids should be 
considered. Following the first four infusions, if the patient experiences no major IRRs, these inhaled post-
infusion medications may be discontinued at the discretion of the physician. 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 34 of 79 
 
 
Other concomitant admitted medications 
Concomitant therapy includes any prescription medications or over-the-counter preparations used by a 
patient between the 7 days preceding the baseline evaluations and the end of last study visit. 
All concomitant medications should be reported to the investigator and recorded on the appropriate CRF. 
The following are supportive therapies that are admitted: 
• Omeprazole 20 mg/day orally or equivalent therapy for peptic ulcer; 
• 5HT3 antagonists or equivalent anti-emetics; 
• Loperamide for the treatment of diarrhea, starting at the time of the first watery stool. The loperamide 
dose regimen should be according to standard practice; 
• Bowel care is recommended to prevent constipation and should be administered per standard 
practice; 
• Platelets and red blood cell transfusion are allowed, if clinically indicated according to local policy; 
• Erythropoietin therapy is allowed if clinically indicated according the ASCO guidelines [49]. 
 
Excluded medications 
Use of the following therapies is prohibited during the study: 
• Cytotoxic chemotherapy (other than study treatment) 
• Other experimental agents 
• Immunotherapy 
• Hormone therapy (other than hormone-replacement therapy, or megestrol acetate) 
• Any therapies intended for the treatment of lymphoma whether European Medicines Agencies (EMA) 
or US Food and Drug Administration (FDA) approved or experimental (outside of this study). 
Patients who require the use of any of these agents will be discontinued from study treatment. 
Treatment with other concomitant anti-tumor agents not defined in this protocol as study treatment or other 
concurrent investigational agents of any type will result in withdrawal of patients from study treatment. 
 
PROPHYLACTIC MEASURES 
 
Hospitalization during the first cycle of therapy 
The first course of D-GDP will be provided as inpatient care, at least until administration of daratumumab 
on day 2 is completed. Following cycles will be administered as outpatient care. 
 
Prevention of daratumumab infusion-related reactions (IRRs) 
Pre-infusion medications should be administered to reduce the risk of infusion-related reactions (IRRs) 
prior to treatment with daratumumab (see also paragraph 13.7.3). 
Patients should be pre-medicated with antihistamines, antipyretics and corticosteroids to reduce the 
risk of IRRs prior to treatment with daratumumab.  
To reduce the risk of delayed IRRs, oral corticosteroids should be administered to all patients following 
daratumumab infusions. Additionally, the use of post-infusion medications (e.g. inhaled corticosteroids, 
short and long acting bronchodilators) should be considered for patients with a history of chronic 
obstructive pulmonary disease to manage respiratory complications should they occur (see paragraph 
13.3.1). 
Daratumumab infusion should be interrupted for IRRs of any severity. Medical management/supportive 
treatment for IRRs should be instituted as needed. The infusion rate should be reduced when re-starting 
the infusion (see paragraph 13.7.3). 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 35 of 79 
 
 
Prophylaxis for tumor lysis syndrome (TLS) 
For patients with high tumor burden and who are considered by the investigator to be at risk for tumor lysis 
syndrome, tumor lysis prophylaxis with hydration and uric-acid reducing agents is recommended prior to 
the initiation of treatment, as per clinical practice. Clinical chemistries should be corrected. Monitor with 
clinical chemistries and manage promptly, as clinically indicated. 
Patients should be well hydrated. Starting 1 or 2 days before the first dose of daratumumab, it is desirable 
to maintain a fluid intake of approximately 3 L/day. In addition, all patients with high tumor burden 
considered at risk for tumor lysis syndrome should be treated with 300 mg/day of allopurinol PO or a 
suitable alternative uric-acid reducing agents treatment starting 48–72 hours prior to Cycle 1, Day 1 of 
treatment and hydration. Patients should continue to receive repeated prophylaxis with allopurinol and 
adequate hydration prior to each subsequent infusion, if deemed appropriate by the investigator. 
 
Mandatory primary neutropenia prophylaxis  
Primary neutropenia prophylaxis is required during the induction period of the treatment. G-CSF should 
be used after each D-GDP cycle from day 3 to 6, and from day 10 to 13; the administration of G-CSF can 
be prolonged after day 13 according to patient requirement and/or local policy and in accordance with 
ASCO guidelines [50].  
 
Prevention of Herpes Zoster infection and Pneumocystis Jiroveci Pneumonia  
Herpes Zoster: 
• 
Antiviral prophylaxis with acyclovir 800 mg at day or valaciclovir 500 mg at day according to local 
policy during the induction and maintenance phases; 
Pneumocystis Jiroveci Pneumonia (PCP): 
• 
Co-Trimoxazole 800 mg/160 mg Forte Tablets 1 tablet on Monday, Tuesday, Friday or Pentamidine 
aerosol every 28 days in patients with Co-Trimoxazole allergy/intolerance or in patients with G6PD 
deficiency according to local policy during the induction and maintenance phase. 
 
Anti-Hyperuricemic therapy 
Allopurinol or other antihyperuricemic drug according to local policy. Consider use of rasburicase if 
subjects baseline uric acid level is elevated. 
 
Prevention and Management of Hepatitis B Virus Reactivation 
Patients with chronic hepatitis B virus (HBV) requiring treatment are excluded from the study. 
Patients with active hepatitis B virus (HBV) are excluded from the study.  
Primary antiviral prophylaxis is permitted as per local standard of care.  Per protocol, HBV DNA testing by 
PCR is mandatory for subjects at risk for HBV reactivation (see Section 15.4). 
The following categories of patients HBV positive but with no evidence of active hepatitis may be 
considered for the study:  
• 
HBsAg positive with HBV DNA < 2000 UI/ml (inactive carriers); HBV DNA > 2000 UI/ml is criteria 
of exclusion  
• 
HBsAg negative but anti-HBs positive 
• 
HBsAg negative but anti-HBc positive  
• 
HBsAg positive with HBV DNA < 2000 UI/ml and HBsAg negative but anti-HBc ± anti-HBs positive 
will be eligible for the study only if they accept to receive prophylactic Lamivudine 100 mg/daily 
for all the period of treatment and at least for 12 months after the end of therapy. Treatment should 
be stopped in case of hepatitis reactivation.  
As far as the monitoring of these patients, the protocol plans:  

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 36 of 79 
 
• 
Patients HBsAg positive with HBV DNA < 2000 UI/ml (inactive carriers): monthly evaluation of 
transaminases and liver function, and bi-monthly evaluation of HBV DNA by PCR; in case of 
hepatitis reactivation or HBV DNA > 2000 UI/ml, treatment should be stopped;  
• 
Patients HBsAg negative but anti-HBc ± anti-HBs positive: monthly evaluation of transaminases, 
liver function and bi-monthly evaluation of HBV DNA by PCR  
As far as prophylactic treatment with Lamivudine:  
- 
Lamivudine 100 mg/daily should be given for all the period and at least for 12 months after the 
end of therapy in inactive carriers (HBsAg positive with HBV DNA < 2000 UI/ml) and in patients 
HBsAg negative but anti-HBc ± anti-HBs positive.  
For subjects who are diagnosed with HBV reactivation while on treatment, study treatment should be 
interrupted until the infection is adequately controlled. If the benefits outweigh the risks, study treatment 
may be resumed with concomitant antiviral prophylaxis as per local standard of care. Consult a liver 
disease specialist as clinically indicated. 
Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic 
marker) and a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR, 
and should be considered eligible for the study. 
 
HCV positive patients 
Patients with chronic hepatitis C virus (HCV) requiring treatment are excluded from the study. 
Patients with active hepatitis C virus (HCV) are excluded from the study. 
Patient with no evidence of active hepatitis and/or advanced chronic liver disease according to liver biopsy 
or fibro-scan evaluation may be included into the study.  
To monitor hepatic function, it is recommended to have a monthly evaluation of transaminases and liver 
function. 
Treatment with D-GDP should be stopped in case of hepatitis reactivation. 
 
CONTRACEPTION 
No clinical or preclinical studies have been performed to evaluate the potential effects of daratumumab on 
reproduction or development. 
Non-sterilized female patients of reproductive age group and male patients should use effective methods 
of contraception through defined periods during and after study treatment as below specified. 
Female patients must meet 1 of the following: 
• 
Postmenopausal for at least 1 year before the screening visit, or 
• 
Surgically sterile, or 
• 
If of childbearing potential, agree to practice 2 effective methods of contraception from the time of 
signing of the informed consent form through 3 months after the last dose of study drug, or 
• 
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) 
and withdrawal are not acceptable methods of contraception. 
Male patients, even if surgically sterilized (i.e., status post vasectomy) must agree to 1 of the following: 
• 
Practice effective barrier contraception during the entire study treatment period and through 3 
months after the last dose of study drug, or 
• 
Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, post ovulation methods 
for the female partner) and withdrawal are not acceptable methods of contraception. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 37 of 79 
 
 
GDP TOXICITY 
Expected Risks and Toxic Effects of gemcitabine 
Safety data presented below are based on single-agent gemcitabine given as treatment for a wide variety 
of malignancies; adverse effects are graded according to World Health Organization (WHO) 
toxicity criteria. 
Hematologic. Myelosuppression is an expected effect of gemcitabine therapy. WHO grade 3 or 4 
hemoglobin toxicity was recorded for 10.5 % of patients. The clinical significance of these results is difficult 
to assess due to disease-related anemia and because investigators differed in the extent to which they 
transfused patients. WHO grade 3 or 4 white blood cell toxicity was seen in 14.4%; incidence of 
neutropenia (WHO grade 3 or 4) was 21.9% and of thrombocytopenia (WHO grade 3 or 4) 10.1%. 
Hemorrhage of grade > 1 WHO was reported in 8.9% of patients (only 0.6% grade 3 or 4). 
Gastrointestinal. Elevated liver function tests, primarily in serum transaminases, occur in roughly one half 
of patients, but rarely (0.1%) required discontinuation of therapy, even in combination studies. WHO grade 
3 or 4 toxicities occurred in 7.1%, 7.2%, 5.6%, and 1.6% of patients for ALT, AST, alkaline phosphatase, 
and bilirubin, respectively. Nausea and vomiting, usually of mild or moderate severity, have been 
commonly reported (63.3%); 11.4% were WHO grade 3 (vomiting severe enough to require therapy) and 
0.7% grade 4 (intractable vomiting). Variability in use of prophylactic antiemetics confounds this 
assessment. Overall, nausea/ vomiting was frequent but rarely dose limiting, manageable with standard 
antiemetics. Grade 2 WHO oral toxicity was reported in 3.3% of patients (erythema or ulcers, no need for 
liquid diet); grade 3 was seen in 0.3%; there were no WHO grade 4 oral toxicities (i.e. rendering 
alimentation impossible). Diarrhea of any severity was reported by 15.6% of patients. 
Renal. Mild (WHO grade 1) proteinuria and hematuria were commonly reported. Hemolytic-uremic 
syndrome (HUS) has been reported; however, renal events outside HUS are very rare, and no causal 
association with gemcitabine can be fully established. 
Fever/Infection. Infections of > WHO grade 1 were reported in 14.5% of patients, 1.9% grade 3 or 4. The 
overall incidence of fever was 36.5%, an indication that gemcitabine may cause fever in the absence of 
clinical infection. Fever was frequently associated with other flu-like symptoms. 
Cutaneous/Hair. A maculopapular rash of mild to moderate severity may appear within 2-3 days of starting 
treatment (27.4% of patients). Mild alopecia was reported in 14.6% of patients. Injection site pain or other 
local reaction was noted in < 3% of patients. 
Neurologic. Somnolence (WHO grade 1 or greater) was reported in 11.5% of patients, asthenia in 8.8%, 
and muscle weakness in 0.4%. Peripheral neurotoxicity, mild and not progressive, was reported for 8.1%. 
Constipation was reported for 20.1% of patients, the majority mild (WHO grade 1).  
Pulmonary. Dyspnea of any severity was reported in 18.8% of patients, WHO grade 3 or 4 (dyspnea at 
rest and dyspnea requiring complete bed rest, respectively) in 3.9%. Occasionally the dyspnea also 
involved bronchospasm (<3% of patients) and was temporally related to the administration of gemcitabine. 
It should be noted that many patients treated in gemcitabine clinical trials had lung cancer or pulmonary 
manifestations of other malignancies. Pulmonary toxicity associated with gemcitabine presents most 
commonly as an acute dyspnea that is not serious; however, serious toxicity including progressive 
dyspnea, pulmonary edema, pneumonitis, and ARDS have been reported. 
Cardiac. WHO grade 4 cardiac function toxicity (symptomatic dysfunction not responsive to therapy) was 
seen in 0.4% of patients, and WHO grade 4 (symptomatic dysfunction responsive to therapy) in 1.3%. 
Cardiac rhythm toxicity (multifocal premature ventricular contractions) WHO grades 3 and 4 have been 
rarely reported. 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 38 of 79 
 
Expected Risks and Toxic Effects of cisplatin 
The dose-limiting toxicity of cisplatin is nephrotoxicity, which may be acute or chronic. While acute renal 
failure may occur within 24 hours of administration in 5-10% of patients, especially those with inadequate 
hydration, renal dysfunction is usually mild and partially reversible in patients receiving < 100 mg/m2/cycle, 
as in this study. Hyperuricemia may indicate cisplatin induced renal toxicity.  
Cumulative ototoxicity has been documented in up to one third of patients treated with cisplatin. 
Neurotoxicity, typically manifested as a sensory peripheral neuropathy, usually reversible, can occur 
during or after cisplatin therapy; treatment should be discontinued if the patient experiences neurological 
symptoms such as loss of motor function, areflexia, loss of proprioception, and aphasia.  
Visual impairment (e.g. blurred vision, altered color perception) is a frequent problem, rarely severe (e.g. 
optical neuritis) and usually reversible.  
Severe nausea and vomiting are a certainty in all patients not pretreated with antiemetics; delayed 
nausea/ vomiting and anorexia occur frequently in patients in whom the acute symptoms are controlled.  
Patients with a prior exposure to platinum (e.g. working in the electronic industry) are particularly 
susceptible to anaphylactoid reactions (facial edema, flushing, wheezing, tachycardia, and hypotension). 
Cisplatin causes less bone marrow suppression than other antineoplastic agents; anemia, neutropenia, 
and thrombocytopenia may occur between days 18-23 following treatment.  
Tissue necrosis after extravasation of >20 ml of concentrated solution has been reported.  
The risk of secondary malignancy increases with cumulative doses > 500 mg.  
Other reactions include hiccups, elevated hepatic enzymes, and alopecia. 
Expected Risks and Toxic Effects of dexamethasone 
Because dexamethasone has been widely used in various situations in medicine for many years, its toxicity 
profile is well known. Reported side effects include hyperglycemia, osteoporosis, mental disturbances, 
gastritis, peptic ulceration, Cushing’s syndrome, and adrenal suppression, but these problems are rare 
when dexamethasone is used for short periods only. 
 
DARATUMUMAB TOXICITY  
 
Indications and Use 
Daratumumab is being developed for the treatment of adult patients with multiple myeloma (MM), that 
highly express CD38 in the malignant cells. Moreover, CD38 is expressed in a large number of 
hematological malignancies and identified as a promising target for antibody-based therapies. 
As of July 2017, daratumumab (DARZALEX®) has been approved in dozens of countries for indications 
as single agent and/or in polychemotherapy; MM who have received at least one prior therapy (second-
line treatment), in association with lenalidomide/dexamethasone or bortezomib/dexamethasone; MM who 
have received at least two prior therapies including lenalidomide and a proteasome inhibitor (third-line 
treatment), in combination with pomalidomide and dexamethasone; MM who have received at least three 
prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or who are double-
refractory to a proteasome inhibitor and an immunomodulatory agent (fourth-line treatment), as 
monotherapy. In May 2018 has been approved by FDA for treatment of newly diagnosed MM (first-line 
treatment) who are ineligible for autologous stem cell transplant in combination with bortezomib, 
melphalan, and prednisone. 
 
Contraindications 
Daratumumab is contraindicated in subjects who have known hypersensitivity (e.g., anaphylactic and 
anaphylactoid reactions) to daratumumab or to the excipients in its formulation. 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 39 of 79 
 
 
Special warnings and precautions for use of daratumumab 
Adverse reactions are adverse events (AEs) that were considered to be reasonably associated with the 
use of daratumumab based on the comprehensive assessment of the available AE information. A causal 
relationship with daratumumab cannot be reliably established in individual cases. Furthermore, because 
clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical 
trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect 
the rates observed in clinical practice. 
The most frequent adverse reactions (> 20%) in individual randomized controlled studies were infusion 
reactions, fatigue, nausea, diarrhea, muscle spasms, pyrexia, cough, dyspnea, neutropenia, 
thrombocytopenia and upper respiratory tract infection. In addition, in combination with bortezomib, 
peripheral edema and peripheral sensory neuropathy were frequently reported. Serious adverse reactions 
were pneumonia, upper respiratory tract infection, influenza, pyrexia, diarrhea, atrial fibrillation. 
A list of expected adverse reactions is provided in Appendix F. 
Infusion-related reactions 
Pre- and post-infusion medications should be administered to reduce the risk of infusion-related reactions 
(IRRs) with daratumumab. 
Infusion-related reactions (IRRs) were reported in approximately half of all patients treated with 
daratumumab. Monitor such patients throughout the infusion and the post-infusion period.  
The majority of IRRs occurred at the first infusion. Four percent of all patients had an IRR at more than 
one infusion. Nearly all reactions occurred during infusion or within 4 hours of completing daratumumab. 
Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal 
edema and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal 
congestion, cough, throat irritation, as well as chills, vomiting and nausea. Less common symptoms were 
wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus and hypotension. 
For IRRs of any grade/severity, immediately interrupt the daratumumab infusion and manage symptoms. 
Management of IRRs may further require reduction in the rate of infusion, or treatment discontinuation of 
daratumumab as below outlined. 
• Grade 1-2 (mild to moderate): Once reaction symptoms resolve the infusion should be resumed at no 
more than half the rate at which the IRR occurred. If the patient does not experience any further IRR 
symptoms, infusion rate escalation may be resumed at increments and intervals as clinically 
appropriate up to the maximum rate. 
• Grade 3 (severe): Once reaction symptoms resolve, restarting of the infusion may be considered at 
no more than half the rate at which the reaction occurred. If the patient does not experience additional 
symptoms, infusion rate escalation may be resumed at increments and intervals as appropriate. The 
procedure above should be repeated in the event of recurrence of Grade 3 symptoms. Permanently 
discontinue daratumumab upon the third occurrence of a Grade 3 or greater infusion reaction. 
• Grade 4 (life-threatening): Permanently discontinue daratumumab treatment. 
Infections 
In patients receiving daratumumab combination therapy, Grade 3 or 4 infections were reported with 
daratumumab combinations and background therapies, with a variable frequency of 19%-28%. Pneumonia 
was the most commonly reported severe (Grade 3 or 4) infection across studies. Discontinuations from 
treatment were reported in 2% to 5% of patients. Fatal infections were reported in 0.8% to 2% of patients 
across studies, primarily due to pneumonia and sepsis. 
Hemolysis 
There is a theoretical risk of hemolysis. Continuous monitoring for this safety signal will be performed in 
clinical studies and post-marketing safety data. 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 40 of 79 
 
Tumor lysis syndrome (TLS) 
Tumor lysis syndrome may be a potential for side effect during daratumumab therapy. There is no data in 
T cell lymphoma and for this reason TLS should be closely monitored during treatment, particularly during 
cycle 1. In general, before initiating treatment, subject risk for developing TLS should be assessed. 
Prophylaxis with hydration and uric-acid reducing agents is recommended. Clinical chemistries should be 
corrected. Monitor with clinical chemistries and manage promptly, as clinically indicated. 
Interference with Serological Testing 
Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test 
(Indirect Coombs test or IAT). Daratumumab-mediated positive indirect antiglobulin test may persist for up 
to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of 
antibodies to minor antigens in the patient’s serum [51]. The determination of a patient’s ABO and Rh 
blood type are not impacted. 
Notify blood transfusion centers of this interference with serological testing and inform blood banks that a 
patient has received daratumumab. Type and screen patients prior to starting daratumumab. 
If an emergency transfusion is required, non-cross-matched ABO/RhD-compatible RBCs can be given per 
local blood bank practices. 
Neutropenia 
Daratumumab may increase neutropenia induced by GDP (see paragraph 13.7.1). Daratumumab dose 
delay may be required to allow recovery of neutrophil count. 
Monitor complete blood cell counts periodically during treatment according to timepoints reported in 
Chapter 15 “Study procedures timepoints”. Monitor patients with neutropenia for signs of infection.  
No dose reduction of Daratumumab is recommended. Consider supportive care with transfusions or 
growth factors. 
Thrombocytopenia 
Daratumumab may increase thrombocytopenia induced by GDP (see paragraph 13.7.1). Daratumumab 
dose delay may be required to allow recovery of platelets. 
Monitor complete blood cell counts periodically during treatment according to timepoints reported in 
Chapter 15 “Study procedures timepoints”.  No dose reduction of Daratumumab is recommended. 
Consider supportive care with transfusions. 
 
Adverse Drug Reactions 
The most frequently reported adverse reactions (incidence ≥20%) were infusion reactions, neutropenia, 
thrombocytopenia, fatigue, nausea, diarrhea, constipation, vomiting, muscle spasms, arthralgia, back pain, 
pyrexia, chills, dizziness, insomnia, cough, dyspnea, peripheral edema, peripheral sensory neuropathy 
and upper respiratory tract infection. See Daratumumab Reference Safety Information (Appendix F). 
 
Special Populations 
Elderly 
No dose adjustments are considered necessary. No clinically important influence of age on the exposure 
to daratumumab was observed in the population pharmacokinetic analyses in patients receiving both 
monotherapy or combination therapies. The difference in exposure was within 6% between younger (age 
< 65 years, n = 352; or age < 75 years, n = 630) and older subjects (age ≥ 65 years, n = 342; or age ≥ 75 
years, n = 64). 
Renal impairment 
No formal studies of daratumumab in patients with renal impairment have been conducted. Based on 
population pharmacokinetic analyses no dosage adjustment is necessary for patients with renal 
impairment. No clinically important differences in exposure to daratumumab monotherapy were observed 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 41 of 79 
 
between patients with renal impairment and those with normal renal function. Additional population 
pharmacokinetic analyses in patients receiving combination treatments also demonstrated no clinically 
important differences in exposure to daratumumab between patients with renal impairment (mild, n = 264; 
moderate, n = 166; severe, n = 12) and those with normal renal function (n = 251). 
Hepatic impairment 
No formal studies of daratumumab in patients with hepatic impairment have been conducted. Changes in 
hepatic function are unlikely to have any effect on the elimination of daratumumab since IgG1 molecules 
such as daratumumab are not metabolized through hepatic pathways. Based on population 
pharmacokinetic analyses, no clinically important differences in the exposure to daratumumab were 
observed between patients with hepatic impairment and those with normal hepatic function. No dosage 
adjustments are necessary for patients with hepatic impairment.  
 
Fertility, pregnancy and lactation 
Women of child-bearing potential/Contraception 
Women of child-bearing potential should use effective contraception during, and for 3 months after 
cessation of daratumumab treatment. 
Pregnancy 
There are no human or animal data to assess the risk of daratumumab use during pregnancy. IgG1 
monoclonal antibodies are known to cross the placenta after the first trimester of pregnancy. Therefore, 
daratumumab should not be used during pregnancy unless the benefit of treatment to the woman is 
considered to outweigh the potential risks to the fetus. If the patient becomes pregnant while taking this 
medicine, the patient should be informed of the potential risk to the fetus. 
Breast-feeding 
It is not known whether daratumumab is excreted into human or animal milk. 
Maternal IgG is excreted in human milk but does not enter the neonatal and infant circulations in substantial 
amounts as they are degraded in the gastrointestinal tract and not absorbed. 
The effect of daratumumab on newborns/infants is unknown. A decision should be made whether to 
discontinue breast-feeding or to discontinue daratumumab therapy taking into account the benefit of breast 
feeding for the child and the benefit of therapy for the woman. 
Fertility 
No data are available to determine potential effects of daratumumab on fertility in males or females (see 
paragraph 7.4.2.). 
 
Interaction with other medicinal products and other forms of interaction 
No interaction studies have been performed. 
As an IgG1қ monoclonal antibody, renal excretion and hepatic enzyme-mediated metabolism of intact 
daratumumab are unlikely to represent major elimination routes. As such, variations in drug-metabolizing 
enzymes are not expected to affect the elimination of daratumumab. Due to the high affinity to a unique 
epitope on CD38, daratumumab is not anticipated to alter drug-metabolizing enzymes. 
 
DRUGS DOSE MODIFICATION  
 
GDP 
The GDP regimens has been extensively adopted as salvage therapy for R/R PTCL [6, 37–48] and 
therefore the results of this study will be compared to historical GDP controls. 
Doses of GDP will be reduced according to the development of severe hematological or non-hematological 
toxicities.  
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 42 of 79 
 
If Hematological Toxicity 
• 
In case of febrile neutropenia, grade 4 thrombocytopenia or grade 4 neutropenia for 7 days: doses 
of gemcitabine and cisplatin will be reduced by 25% in following cycles; if the same grade 4 
hematological toxicity will occur again, doses will be reduced by 50% of the initial dosage. 
If non-hematological Toxicity 
• 
In case of any grade 3 non-hematological toxicities (except alopecia), doses of gemcitabine and 
cisplatin will be reduced by 25% in following cycles; if the same grade 3 non-hematological toxicity 
will occur again, doses will be reduced by 50% of the initial dosage.  
• 
In case of grade 2 neurological toxicity, dose of cisplatin will be reduced by 50% in following cycles; 
cisplatin will be discontinued with the occurrence of > grade 2 neurological toxicity. 
• 
D-GDP therapy will be discontinued with the occurrence of any grade 4 non-hematological 
toxicities.  
Alcohol content of gemcitabine: Doses of gemcitabine not available as ready- made infusions contain up 
to approximately 11g of ethanol (1.5units). Patients should be advised not to drive on the day of treatment. 
Where alcohol content is a concern please contact pharmacy for advice about alternative formulations.  
 
Daratumumab 
No dose reductions of daratumumab are recommended. Dose delay may be required to allow recovery  
of blood cell counts in the event of hematological toxicity. 
Daratumumab may increase neutropenia and thrombocytopenia induced by GDP (see paragraphs 13.7.3. 
and 13.8.1). 
Monitor complete blood cell counts periodically during treatment according to what reported in Chapter 15 
“Study procedures timepoints”. Monitor patients with neutropenia for signs of infection.  
Consider supportive care with transfusions or growth factors. 
 
REMOVAL OF SUBJECTS FROM TREATMENT AND/OR 
STUDY 
 
DISCONTINUATION FROM STUDY TREATMENT 
A subject must be discontinued from study treatment in case of: 
• 
patient withdraws consent to receive protocol treatment; 
• 
disease progression at any time; 
• 
occurrence of an unacceptable toxicity at any time; 
• 
the investigator believes that for safety reasons it is in the best interest of the subject to discontinue 
the treatment. 
 
WITHDRAWAL OF SUBJECTS FROM THE STUDY 
A subject has the right to withdraw from the study at any time and for any reason without prejudice to his 
or her future medical care by the physician or at the institution. 
Circumstances that lead to premature withdrawal of a patient from the trial must be reported by the 
investigator on the appropriate CRF page. 
If the patient withdraws the consent or doesn’t fulfill the inclusion criteria, he must be considered off 
protocol. 
At the time of withdrawal all study procedures outlined for the end of treatment should be completed. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 43 of 79 
 
 
WITHDRAWAL OF CONSENT 
Patients are free to withdraw from the study at any time without prejudice to their treatment. When a patient 
decides to withdraw from the study, she/he should always be contacted to record any adverse events and 
all the evaluable study endpoints. When possible, the patient should return for a study visit at the time of, 
or soon after withdrawal, and the relevant assessments should be performed.  
If the patient explicitly states his/her wish not to contribute further data to the study, the assigned FIL Study 
Coordinator should be informed, and the withdrawal of consent should be documented by the investigator 
in the patient’s case report form.  
Information from subsequent ambulatory visits, laboratory or instrumental assessments and any other 
information on the patient status after consent withdrawal won’t be collected in the data base or used for 
analysis. However, both clinical data collected until patient’s withdrawal as well as the data coming from 
the central review will still be considered as available for the study analysis. 
 
PATIENTS LOST TO FOLLOW UP 
Every effort will be made to contact patients who fail to return for scheduled visits. A patient is considered 
lost to follow-up if no information has been obtained when the last patient has completed the clinical phase 
of the study. During this time site investigator must document attempts to contact the patient either by 
phone or letter. 
 
PREMATURE TERMINATION OF THE STUDY 
The sponsor, in agreement with the DSMC, may decide to prematurely stop the trial at any time based on 
the following criteria: 
- 
one the stopping rules has been reached (see paragraph 18.3);  
- 
there is evidence of other unacceptable risks for study patients beyond the safety stopping rules; 
- 
it will not be possible to reach the planned sample size within reasonable time; 
- 
other justified reasons (i.e., availability of new very effective treatments).  
 
The sponsor will inform  of this decision in writing all concerned investigators, IECs and regulatory 
authorities. The sponsor will provide information regarding the timelines of study termination and 
instructions regarding treatment and data collection of enrolled patients. 
The same applies to any investigator willing to discontinue his/her participation to the trial. The investigator 
must immediately inform the sponsor in writing of this decision, giving assurance of providing data for all 
patients already enrolled. 
 
STUDY PROCEDURES TIMEPOINTS 
 
SCREENING PERIOD  
Within 4 weeks prior to start of the therapy 
Screening procedures are per clinical practice of refractory/relapsed PTCL. All screening assessments 
must be completed within 28 days prior to the beginning of therapy with the exception of the tumor biopsy 
and the bone marrow biopsy, which may occur up to 3 months prior to C1D1, and the PET and CT scans, 
which may occur up to 6 weeks prior to C1D1. Relapse biopsy, or in the more recent biopsy in the case of 
refractory patients, will be centralized to the FIL designated laboratory for centralized pathology 
assessment and CD38 positivity after the subject has signed the informed consent. A core needle biopsy 
is considered sufficient for diagnosis review and CD38 evaluation; Note: Patients with only bone marrow 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 44 of 79 
 
involvement are eligible. In patients with only bone marrow lymphoma infiltration central diagnosis review 
and CD38 evaluation can be performed in bone marrow sections.  
Only patients with percentage of CD38 positive tumor cells ≥ 5% will be considered eligible for protocol 
study treatment. 
The screening period procedures include: 
- Check for inclusion/exclusion criteria 
- Written Informed Consent; 
- Complete Medical History; 
- Lymph Node/Tumor biopsy material (formalin-fixed, paraffin-embedded) available to centralize 
(mandatory) (see Chapter 20 and Appendix E); 
- Physical Examination including height and weight; 
- ECOG performance status; 
- Vital Signs (blood pressure, pulse rate and body temperature); 
- B symptoms; 
- Hematology including hemoglobin, hematocrit, platelet (PLT), red blood cell (RBC), white blood cell 
count (WBC) with absolute differential count (neutrophils, lymphocytes, monocytes, basophils, and 
eosinophils); 
- Biochemistry including AST, ALT, serum alkaline phosphatase, gGT, total bilirubin, LDH, creatinine, 
Na, K, Ca, uric acid, total protein, albumin and creatinine clearance; 
- IgA, IgG, IgM; 
- Coagulation assessment: PTT, PT; 
- Determination of ABO and Rh blood type and Indirect Coombs test (IAT); 
- Serology for HBV (refer also to paragraph 15.4):  
- 
hepatitis B surface antigen (HBsAg) 
- 
hepatitis B surface antibody (Anti-HBs) 
- 
hepatitis B core antibody (Anti-HBc) 
Subjects who are positive for Anti-HBc or Anti-HBs will undergo testing for hepatitis B DNA by PCR; 
- Serology for HCV, HIV; 
- Contrast enhanced CT scan including neck, chest, abdomen and pelvis (MRI can be used alter-natively 
to CT scan) plus PET scan or, in alternative, a PET-CT scan;  
- ECG; 
- LVEF by bi-dimensional echocardiogram;  
- Pregnancy test (if applicable); 
- Bone marrow biopsy; 
- Concomitant medications; 
- Reporting of AE occurred during the screening phase. 
 
INDUCTION PHASE  
During cycle 1: weekly evaluation of 
- Physical Examination; 
- ECOG performance status; 
- Vital Signs (blood pressure, pulse rate and body temperature); 
- Hematology including hemoglobin, hematocrit, PLT, RBC, WBC with absolute differential count; 
- Biochemistry including potassium, uric acid, phosphorus, calcium and creatinine; 
Before each subsequent cycle therapy (Cycles 2-6) 
- Physical Examination; 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 45 of 79 
 
- ECOG performance status; 
- Vital Signs (blood pressure, pulse rate and body temperature); 
- Hematology including hemoglobin, hematocrit, PLT, RBC, WBC with absolute differential count; 
- Biochemistry including AST, ALT, serum alkaline phosphatase, gGT, total bilirubin, LDH, creatinine, 
Na, K, Ca, uric acid; 
- Concomitant medications reporting; 
- Reporting of AE occurred during the previous cycle. 
During each subsequent cycle of therapy (Cycles 2-6): weekly evaluation of 
- Hematology including hemoglobin, hematocrit, PLT, RBC, WBC with absolute differential count. 
 
MAINTENANCE PHASE  
Before each maintenance cycle 
- Physical Examination; 
- ECOG performance status; 
- Vital Signs (blood pressure, pulse rate and body temperature); 
- Hematology including hemoglobin, hematocrit, PLT, RBC, WBC with absolute differential count; 
- Biochemistry including AST, ALT, serum alkaline phosphatase, gGT, total bilirubin, LDH, creatinine, 
Na, K, Ca, uric acid; 
- Concomitant medications reporting; 
- Reporting of AE occurred during previous cycle (starting from cycle 2). 
 
HBV STUDY EVALUATIONS 
• 
HBV Serology 
All subjects will be tested locally for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody 
(Anti-HBs), and hepatitis B core antibody (Anti-HBc) at Screening.  
• 
HBV DNA Tests 
Subjects who are positive for Anti-HBc or Anti-HBs will undergo testing for hepatitis B DNA by PCR. 
Subjects with serologic findings suggestive of HBV vaccination (Anti-HBs positivity as the only serologic 
marker) and a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR. 
During and following study treatment, subjects who have history of HBV infection (HBsAg negative and 
anti-HBc ± anti-HBs positive and with undetectable HBV DNA levels at screening) will be closely 
monitored for clinical and laboratory signs of reactivation of HBV: HBV DNA levels in PCR must be 
followed approximately every 2 months for up to 12 months after the last dose of daratumumab. 
Where required by local law, the results of HBV testing may be reported to the local health authorities. 
 
RESTAGING AFTER 4 COURSES OF INDUCTION 
To be performed on day 12 to 19, cycle 4 
- Physical Examination; 
- ECOG performance status; 
- Vital Signs (blood pressure, pulse rate and body temperature); 
- Hematology including hemoglobin, hematocrit, PLT, RBC, WBC with absolute differential count; 
- Biochemistry including AST, ALT, serum alkaline phosphatase, gGT, total bilirubin, LDH, creatinine, 
Na, K, Ca, uric acid; 
- IgA, IgG, IgM; 
- ECG; 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 46 of 79 
 
- LVEF by bi-dimensional echocardiogram; 
- Contrast enhanced CT scan including neck, chest, abdomen and pelvis (or MRI, if used at baseline 
staging); 
- Bone marrow biopsy (if positive at baseline) only to confirm a CR (NB: once a CR has been confirmed 
no other bone morrow biopsies are required); 
- Any other radiological (PET or PET/CT scan included), clinical and laboratory procedures if indicated 
to confirm a CR or if clinically indicated; 
- Response assessment according to Lugano 2014 criteria [52], Appendix D; 
- Reporting of AE occurred during cycle 4. 
 
RESTAGING AT EOI (END OF INDUCTION PHASE)  
To be performed on day 15 to 25, cycle 6  
- Physical Examination; 
- ECOG performance status; 
- Vital Signs (blood pressure, pulse rate and body temperature); 
- Hematology including hemoglobin, hematocrit, PLT, RBC, WBC with absolute differential count; 
- Biochemistry including AST, ALT, serum alkaline phosphatase, gGT, total bilirubin, LDH, creatinine, 
Na, K, Ca, uric acid; 
- Contrast enhanced CT scan including neck, chest, abdomen and pelvis (or MRI, if used at previous 
assessments); 
- Response assessment according to Lugano 2014 criteria [52], Appendix D; 
- Bone marrow biopsy (if positive at baseline) only to confirm a CR; 
- Any other radiological (PET or PET/CT scan included), clinical and laboratory procedures if indicated 
to confirm a CR or if clinically indicated; 
- Reporting of AE occurred during cycle 6. 
 
RESTAGING DURING MAINTENANCE 
Every 3 cycles up to cycle 12, then every 4 cycles from cycle 13 to 24 
- Physical Examination; 
- ECOG performance status; 
- Vital Signs (blood pressure, pulse rate and body temperature); 
- Hematology including hemoglobin, hematocrit, PLT, RBC, WBC with absolute differential count; 
- Biochemistry including AST, ALT, serum alkaline phosphatase, gGT, total bilirubin, LDH, creatinine, 
Na, K, Ca, uric acid; 
- Contrast enhanced CT scan including neck, chest, abdomen and pelvis (or MRI, if used at previous 
assessments); 
- Bone marrow biopsy (if positive at baseline) only to confirm a CR; 
- Any other radiological (PET or PET/CT scan included), clinical and laboratory procedures if indicated 
to confirm a CR or if clinically indicated;  
- Response assessment according to Lugano 2014 criteria [52], Appendix D; 
 
RESTAGING AT THE EOT (REGARDLESS OF THE REASON FOR DISCONTINUATION) 
- Physical Examination; 
- ECOG performance status; 
- Vital Signs (blood pressure, pulse rate and body temperature); 
- Hematology including hemoglobin, hematocrit, PLT, RBC, WBC with absolute differential count 
(neutrophils, lymphocytes, monocytes, basophils, and eosinophils); 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 47 of 79 
 
- Biochemistry including AST, ALT, serum alkaline phosphatase, gGT, total bilirubin, LDH, creatinine, 
Na, K, Ca, uric acid, total protein, albumin; 
- IgA, IgG, IgM; 
- ECG; 
- LVEF by bi-dimensional echocardiogram;  
- Contrast enhanced CT scan including neck, chest, abdomen and pelvis (or MRI, if used at previous 
assessments); 
- Response assessment according to Lugano 2014 criteria [52], Appendix D; 
- Bone marrow biopsy (if positive at baseline) only to confirm a CR; 
- Any other radiological (PET or PET/CT scan included), clinical and laboratory procedures (including 
biopsy of suspicious extranodal sites) if indicated to confirm a CR or if clinically indicated; 
- Reporting of AE occurred during the last cycle administered. 
 
ASSESSMENTS DURING FOLLOW-UP 
After treatment discontinuation, both in the case the protocol treatment was fully administered and in the 
case of an early discontinuation, patients will be followed-up according to clinical practice timeline and 
procedures, and information on patient status (progression/relapse, alive/dead, lost to follow-up) will be 
collected till the end of the study (LPLV), planned 24 months after the start of induction treatment of last 
patient enrolled. In case of progression/relapse during follow-up, the patients will be then followed-up for 
survival till the study end. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 48 of 79 
 
 
 SCHEDULE OF ASSESSMENTS 
 
Screening 
(All) 
Induction 
Maintenance 
FU 
-28 to D1 
as per 
clinical 
practice 
 
Cy 1 
 
Cy 2-6 
 
After Cy 4 
 
EOI 
Before 
each 
cycle 
Every 3 
cycles Cy 
1-12 and 
every 
4 cycles Cy 
12-24 
EOT* 
as per 
clinical 
practice 
 
D1 
D1 
D1 
 
 
D1 
 
 
 
 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
Inclusion/Exclusion 
X 
 
 
 
 
 
 
 
Lymph Node/Tumor biopsy 
material available for 
central review 
X 
 
 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
 
 
Physical exam a 
X 
Xw 
X 
X 
X 
X 
X 
X 
Pregnancy test b 
X 
 
 
 
 
 
 
 
ECOG PS 
X 
Xw 
X 
X 
X 
X 
X 
X 
B symptoms 
X 
 
 
 
 
 
 
 
Hematology tests c 
X 
X c, w 
X c, w 
X c 
X c 
X 
X 
X 
Biochemistry d 
X 
Xw 
X 
X 
X 
X 
X 
X 
IgA, IgG, IgM 
X 
 
 
X 
 
 
 
X 
Coagulation (PT, PTT) 
X 
 
 
 
 
 
 
 
ABO/Rh and IAT 
X 
 
 
 
 
 
 
 
Bone marrow biopsy g 
X 
 
 
X g 
X g 
 
X g 
X g 
Tumor assessment 
(TB CT scan, MRI, PET) h 
X 
 
 
X 
X 
 
X 
X 
ECG 
X 
 
 
X 
 
 
 
X 
LVEF echo 
X 
 
 
X 
 
 
 
X 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 49 of 79 
 
Other procedures i 
 
 
 
X 
X 
 
X 
X 
Response assessment 
 
 
 
X 
X 
 
X 
X 
Serology 
X e 
X f 
Concomitant medications j 
Recorded from screening through 30 days after the last dose of treatment. 
Adverse event reporting k 
Recorded from signing of the informed consent through 30 days after the last dose of treatment. 
Serious adverse event k 
Recorded from signing of the informed consent form through LPLV. 
 
 
 
*  
EOT for any reason, including early withdrawal and PD/relapse 
a. 
Physical examination including vital signs (blood pressure, pulse rate, height, weight) with measurement of all palpable disease. 
b. 
For women of childbearing potential only: pregnancy test within 7 days prior to study drugs administration (or within 14 days if with a confirmatory urine 
pregnancy test within 7 days prior to the first study drugs administration). 
c. 
Clinical laboratory evaluations (blood count with differential white count) to be performed weekly during induction 
d. 
Biochemistry (AST, ALT, serum alkaline phosphatase, gGT, total bilirubin, LDH, creatinine, Na, K, Ca, uric acid, total protein, albumin, creatinine 
clearance). During cycle 1 weekly assessment of biochemistry including potassium, uric acid, phosphorus, calcium and creatinine 
e. 
Standard HIV and HCV; HBV serology includes HBsAg, anti-HBc, anti-HBs and HBV-DNA in PCR in patients positive to anti-HBc ± anti-HBs; 
f. 
In patients who are HBsAg negative and anti-HBc ± anti-HBs positive and with undetectable HBV DNA levels at screening, HBV DNA levels by PCR 
must be followed approximately every 2 months for up to 12 months after the last dose of daratumumab (see paragraph 15.4). 
g. 
Bone marrow to be repeated at restaging with the aims to confirm a CR, and only if positive at baseline. If bone marrow clears during treatment, no 
additional test to be performed. 
h. 
During the screening, contrast enhanced CT scan, including neck, chest, abdomen and pelvis (or MRI, if CT-scan cannot be done)) + PET scan or 
alternatively, a combined PET-CT (allowed if CT resolution meets Central Radiology’s minimum threshold); during subsequent evaluation PET is 
allowed if of clinical relevance but not mandatory. 
i. 
Any other radiologic, clinical and laboratory procedures (including biopsy of suspicious sites) if indicated to confirm a CR or if clinically indicated. 
j. 
Concomitant medications must be collected from the time of informed consent signature, throughout the treatment period and up to and including 30 
days post-study follow-up period. 
k. 
Adverse events must be collected from the time of signature of informed consent throughout the treatment period and until completion of the last 
subject’s related procedure which includes contact for follow-up of safety. All SAEs must be reported within 24 hours. All AEs and SAEs must be 
followed up until resolution unless in the opinion of the investigator the condition is unlikely to resolve due to the patient’s underlying disease. 
w. weekly evaluation of hematology including hemoglobin, hematocrit, PLT, RBC, WBC with absolute differential count. 
 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 50 of 79 
 
 
EFFICACY MEASUREMENTS AND PARAMETERS 
 
EFFICACY MEASUREMENT 
The primary analysis population for all efficacy and safety analyses includes all 35 subjects who 
received at least 1 dose of planned therapy. 
Efficacy will be measured by: 
• 
Computed tomography (CT) scans with contrast of the neck, chest, abdomen and pelvis plus 
Positron emission tomography (PET) scan of the whole body or a CT-PET will be performed 
at baseline and after 3 cycles of treatment. Subsequently, CT scan will be performed every 
3 cycles during the first 12 cycles and every 4 cycles from cycle 13 to 24; PET will be repeated 
only to confirm a CR status evaluated with CT. For those patients still on therapy after 24 
cycles, the response evaluation, after this time, will be performed every 6 cycles. 
• 
MRI may be used instead of CT scan in patients for whom CT scans with contrast are 
contraindicated. 
• 
Bone marrow biopsy will be performed at baseline and subsequently to confirm first CR only 
in patients who were positive for lymphoma infiltration at baseline. 
• 
For the evaluation of response, the response criteria (PET-based or CT-based of the Lugano 
Classification will be adopted) [52]. 
 
EFFICACY PARAMETERS  
 
Primary efficacy endpoint 
Complete Response Rate (CRR) after 4 cycles of D-GDP. CRR will be defined as the proportion 
of patient in CR according to Lugano classification response Criteria (Appendix D) [52] after the first 
4 cycles of D-GDP. In case of early discontinuation, efficacy will be assessed at the EOT visit. 
Patients without response assessment (due to whatever reason) will be considered as non-
responders.  
 
Secondary efficacy endpoints 
Overall Response Rate (ORR). ORR will be assessed after the first 4 cycles and at each restaging 
and defined according to the Lugano 2014 criteria (Appendix D) [52], including the sum of CR + PR. 
Response assessment will be done at each restaging. The best overall response will be defined as 
the best response between the date of beginning of therapy and the last restaging. Patients without 
response assessment (due to whatever reason) will be considered as non-responders. 
Overall Survival (OS) will be defined from the date of starting therapy and the date of death from 
any cause. Patients alive and those who are lost to follow-up at the time of the final analysis will be 
censored at the date of the last contact. 
Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of 
disease progression, relapse or death from any cause. Responding patients according to the Lugano 
classification response Criteria (Appendix D) [52] and patients who are lost to follow-up will be 
censored at their last assessment date. 
 
Explorative efficacy endpoints 
Role of daratumumab maintenance by comparison of CRR before and after maintenance, and by 
evaluation of rate of conversion in CR with daratumumab maintenance for patients in PR after the 
induction. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 51 of 79 
 
Association between intensity of CD38 expression and response. The extent of CD38 
expression evaluated by the central FIL designed laboratory will be correlated with response 
measured according to the Lugano 2014 criteria at various endpoints. 
 
SAFETY MEASUREMENTS AND PARAMETERS 
 
SAFETY MEASUREMENTS 
All patients who have received at least 1 dose of study medication will be considered for the safety 
analysis and will be evaluated for toxicity from the time of their first drug administration. When toxicity 
occurs, it should be graded according to the NCI Common Toxicity Criteria, version 5.0.  
During the first 4 cycles of therapy, ADRs and AEs will be evaluated with the aim of monitoring 
toxicity for stopping rules assessment according to the modalities hereafter reported. The same 
modalities will be applied also for further evaluation at timepoints reported in Chapter 15.   
 
Definition of relevant toxicity 
Relevant toxicity will be defined as the proportion of patients experiencing one or more of the 
following events:  
- 
grade 4 neutropenia lasting more than 7 days regardless adequate G-CSF primary 
prophylaxis/treatment; 
- 
grade 4 thrombocytopenia lasting more than 7 days; 
- 
this definition does not apply to the 1st cycle for patients presenting with cytopenias defined 
as absolute neutrophil count <1,000 cells/µL and platelets <100,000 cells/µL which is related 
to marrow involvement. For this particular subgroup of patients, hematological relevant toxicity 
will be assessed starting from the 2nd cycle; 
- 
any grade 3-4 non-hematological toxicity drug related with special regard to infections and 
tumor lysis syndrome (excluding alopecia, laboratoristic data and IRR); 
- 
delay ≥ 15 days in the next course administration; 
- 
febrile neutropenia lasting for more than 7 consecutive days. 
 
SAFETY PARAMETERS 
 
Adverse Events (AEs) and Adverse Drug Reactions (ADRs) 
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
subject administered a medicinal (investigational or non-investigational) product and which does not 
necessarily have to have a causal relationship with this treatment [Dir 2001/20/EC Art 2(m)]. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding, for example), symptom, or disease temporally associated with the use of a medicinal 
(investigational or non-investigational) product, whether or not considered related to the medicinal 
(investigational or non-investigational) product. This includes any occurrence that is new in onset or 
aggravated in severity or frequency from the baseline condition, or abnormal results of diagnostic 
procedures, including laboratory test abnormalities. 
In the context of a clinical trial: any untoward medical occurrence in a subject to whom a medicinal 
product is administered and which does not necessarily have a causal relationship with this treatment 
[Reg (EU) No 536/2014 Art 2(2)(32)] 
Adverse drug reaction (ADR) is a response to a medicinal product which is noxious and unintended 
[DIR 2001/83/EC Art 1(11)], this meaning that if there is at least a reasonable possibility of a causal 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 52 of 79 
 
relationship between a medicinal product and an adverse event, it should be sufficient reason for 
reporting. 
Adverse reactions may arise from use of the product within or outside the terms of the marketing 
authorization or from occupational exposure [DIR 2001/83/EC Art 101(1)]. Use outside the marketing 
authorization includes off label use, overdose, misuse, abuse and medication errors. 
 
Serious Adverse Events (SAE) 
A serious adverse event (SAE) based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any untoward medical occurrence that at any dose: 
- 
Results in death (the subject was at risk of death at the time of the event. It does not refer to 
an event that hypothetically might have caused death if it were more severe); 
- 
Is life-threatening (the term "life-threatening" in the definition of "serious" refers to an event in 
which the patient was at risk of death at the time of the event; it does not refer to an event 
which hypothetically might have caused death if it were more severe); 
- 
Requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization is 
defined as an inpatient admission, regardless of length of stay); 
- 
Results in persistent or significant disability/incapacity; 
- 
Is a congenital anomaly/birth defect; 
- 
Is a suspected transmission of any infectious agent via a medicinal product; 
- 
Is a medically significant event. 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriated in other situations, such as important medical events that may not be immediately life-
threatening or result in death or hospitalization but may jeopardize the patient or may require 
intervention to prevent one of the outcomes listed in the definition above. 
The term “severe” is a measure of intensity, thus a severe AE is not necessarily serious. For 
example, “nausea of several hours” duration may be severe but may not be clinically serious. 
 
Events not considered to be SAEs are hospitalizations for: 
- 
A standard procedure for protocol therapy administration. However, hospitalization or 
prolonged hospitalization for a complication of therapy administration will be reported as an 
SAE.  
- 
Routine treatment or monitoring of the studied indication not associated with any deterioration 
in condition. 
- 
The administration of blood or platelet transfusion as routine treatment of studied indication.  
However, hospitalization or prolonged hospitalization for a complication of such transfusion 
remains a reportable SAE. 
- 
A procedure for protocol/disease-related investigations (e.g., surgery, scans, endoscopy, 
sampling for laboratory tests, bone marrow sampling).  However, hospitalization or prolonged 
hospitalization for a complication of such procedures remains a reportable SAE. 
- 
Hospitalization or prolongation of hospitalization for technical, practical, or social reasons, in 
absence of an AE. 
- 
A procedure that is planned (i.e., planned prior to starting of treatment on study); must be 
documented in the source document and the CRF. Hospitalization or prolonged hospitalization 
for a complication remains a reportable SAE. 
- 
An elective treatment of a pre-existing condition unrelated to the studied indication. 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 53 of 79 
 
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form on 
www.drugvigilance.filinf.it must be completed. 
For each SAE, the Investigator will provide information on severity, start and stop dates, relationship 
to investigational product (IP), action taken regarding IP, and outcome. 
 
Suspected Unexpected Serious Adverse Reaction (SUSAR) 
An unlisted adverse event, the nature or severity of which is not consistent with the applicable 
product reference safety information. For an investigational drug, the expectedness of an adverse 
event will be determined by whether or not it is listed in the Investigator's Brochure (IB) of 
experimental drug. For drugs with a marketing authorization, the expectedness of an adverse event 
will be determined by whether or not it is listed in the related reference safety information document 
(IB or SMPC). 
 
Severity 
The intensity of the toxicities, AE or SAE will be graded by the investigator according to the Common 
Terminology Criteria for Adverse Events (CTCAE) grading system v 5.0 in the toxicity categories that 
have recommended grading (follow the link or see Investigator’s file). 
AEs not listed on this grading system will be graded according to the five-point system below: 
Mild (grade 1) 
Discomfort noticed but no disruption of normal 
daily activity 
Moderate (grade 2) 
Discomfort sufficient to reduce or affect normal 
daily activity 
Severe (grade 3) 
Incapacitating with inability to work or perform 
normal daily activity 
Life-threatening (grade 4) 
Substantial risk of dying at time of event 
Death (grade 5) 
Fatal 
 
 
Causality 
The Investigator(s) must determine the relationship between the administration of study drug and 
the occurrence of an AE/SAE as Not Suspected or Suspected as defined below: 
- 
Not related. An adverse event that is not related to the use of the investigational product. 
- 
Unlikely/Doubtful. An AE for which an alternative explanation is more likely, e.g., concomitant 
drug(s), concomitant disease(s), or the relationship in time suggests that a causal relationship 
is unlikely. 
- 
Possible. An AE that might be due to the use of the investigational product. An alternative 
explanation, e.g., concomitant drug(s), concomitant disease(s), is inconclusive. The 
relationship in time is reasonable; therefore, the causal relationship cannot be excluded. 
- 
Probable. An AE that might be due to the use of the investigational product. The relationship 
in time is suggestive (e.g., confirmed by dechallenge). An alternative explanation is less likely, 
e.g., concomitant drug(s), concomitant disease(s). 
- 
Definite/Very likely. An AE that is listed as a possible adverse event reaction, and cannot be 
reasonably explained by an alternative explanation, e.g., concomitant drug(s), concomitant 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 54 of 79 
 
disease(s). The relationship in time is very suggestive (e.g., it is confirmed by dechallenge and 
rechallenge). 
 
SERIOUS ADVERSE EVENTS REPORTING RULES 
All events that meet one or more criteria of seriousness (see paragraphs 17.2.2 and the present 
paragraph) occurred after the informed signature until completion of the last subject’s related 
procedure which includes contact for follow-up of safety, which may include contact for follow-up of 
safety and regardless of the relationship to the study treatment, will be reported as SAE. 
The SAE that occurs during the follow-up period, if considered related to the study medication, will 
be reported.  
Whenever possible, symptoms should be grouped as a single syndrome or diagnosis. The 
investigator should specify the date of onset, intensity, action taken regarding trial medication, 
corrective therapy given, outcome of all SAEs and his opinion as to whether the SAE can be related 
to the study drugs. 
 
General SAE reporting rules 
- 
Any episode of any grade of adverse events, which meets one of the seriousness criteria, must 
be 
reported 
as 
“Serious 
Adverse 
Event” 
on 
the 
FIL 
drugvigilance 
platform 
www.drugvigilance.filinf.it.  
- 
Signs, symptoms and physical findings indicative of lymphoma or progression of lymphoma 
are not to be reported as “Serious Adverse Event”. 
- 
“Alopecia” toxicity (any grade) will never be reported as “Serious Adverse Event”. 
 
All AEs that occur from the time a signed and dated ICF is obtained until completion of the last 
subject’s related procedure which includes contact for follow-up of safety will be recorded in the 
source documents and the CRF. 
All SAEs that occur between the study informed consent signature and until completion of the last 
subject’s related procedure which includes contact for follow-up of safety will be notified to the 
sponsor by study-site personnel within 24 hours of their knowledge of the event through the FIL 
platform www.drugvigilance.filinf.it by using the FIL Serious Adverse Event reporting rules.  
The sponsor will evaluate any safety information that is spontaneously reported by an investigator 
beyond the time frame specified in the protocol. 
 
All AEs and SAEs regardless of seriousness, severity, or presumed relationship to study therapy, 
must be recorded in the CRF and source documents in accordance to the CTCAE criteria v 5.0.  
All safety information must be recorded using Medical Dictionary for Regulatory Activities 
Terminology (MedDRA). 
Timely, accurate, and complete reporting and analysis of safety information from clinical studies are 
crucial for the protection of subjects, investigators, and the sponsor, and are mandated by regulatory 
agencies worldwide. 
 
Method of Detecting Adverse Events and Serious Adverse Events 
Care will be taken not to introduce bias when detecting adverse events or serious adverse events. 
Open-ended and nonleading verbal questioning of the subject is the preferred method to inquire 
about adverse event occurrence.  
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 55 of 79 
 
Solicited Adverse Events 
Solicited adverse events are predefined local and systemic events for which the subject is specifically 
questioned. 
 
Unsolicited Adverse Events 
Unsolicited adverse events are all adverse events for which the subject is specifically not questioned. 
 
Special Reporting Situations 
Safety events of interest on a clinical trial that may require expedited reporting or safety evaluation 
include, but are not limited to: 
• 
drugs exposure during pregnancy (paternal, maternal)  
• 
suspected transmission of any infectious agent via administration of the medicinal products  
• 
exposure to the  medicinal products from breastfeeding  
• 
overdose of the medicinal products 
• 
medication error, intercepted medication error or potential medication error  
• 
suspected abuse/misuse of the medicinal products,  
- 
unexpected therapeutic benefit or clinical benefit from use of the medicinal products 
inadvertent or accidental exposure to the medicinal products 
Special reporting situations (including SRSs not associated to an event) must be reported using the 
Serious Adverse Event Form  following the rules and timelines of SAE reporting, as a sponsor 
procedure. 
 
Obligations of the Investigator 
Investigator(s) must record also in the CRF their opinion concerning the relationship of the adverse 
event to the study therapy. All measures required for adverse event management must be recorded 
in the source document and reported according to promoter instructions.  
Investigators must submit reports of all SAEs, regardless of attribution, Pregnancy Reports, Special 
Reporting Situations, Product Quality Complaints to the Sponsor within 24 hours of learning of the 
events.  
For initial SAE investigators should record all case details that can be gathered on a SAE form that 
must be completed directly online through the FIL web site: 
www.drugvigilance.filinf.it 
The initial report must be as complete as possible, including details of the current illness and serious 
adverse event, and an assessment of the causal relationship between the event and the 
investigational product(s). Information not available at the time of the initial report (e.g., an end date 
for the adverse event or laboratory values received after the report) must be documented on a follow-
up SAE form as soon as it becomes available and/or upon request. 
The Investigator(s) must keep copies of all SAE information on file. All SAEs that have not resolved 
by the end of the study, or that have not resolved upon discontinuation of the patient’s participation 
in the study must be followed until any of the following occurs: 
- 
The event resolves; 
- 
The event stabilizes; 
- 
The event returns to baseline, if a baseline value/status is available; 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 56 of 79 
 
- 
The event can be attributed to agents other than the study intervention or to factors unrelated 
to study conduct; 
- 
It becomes unlikely that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow-up after demonstration of 
due diligence with follow-up efforts). 
Suspected transmission of an infectious agent by a medicinal product will be reported as a serious 
adverse event.  
Any event requiring hospitalization (or prolongation of hospitalization) that occurs during the course 
of a subject's participation in a study must be reported as a serious adverse event, except 
hospitalizations for the following:  
- 
Hospitalizations not intended to treat an acute illness or adverse event (e.g., social reasons 
such as pending placement in long-term care facility); 
- 
Surgery or procedure planned before entry into the study (must be documented in the CRF). 
Note: Hospitalizations that were planned before the signing of the ICF, and where the 
underlying condition for which the hospitalization was planned has not worsened, will not be 
considered serious adverse events. Any adverse event that results in a prolongation of the 
originally planned hospitalization is to be reported as a new serious adverse event; 
- 
For convenience the investigator may choose to hospitalize the subject for the duration of the 
intervention period. 
Disease progression should not be recorded as an adverse event or serious adverse event term; 
instead, signs and symptoms of clinical sequelae resulting from disease progression/lack of efficacy 
will be reported if they fulfill the serious adverse event definition. 
Contact Details for Pharmacovigilance 
Name: FIL Pharmacovigilance Department 
: +39.0131.033156        
Fax: +39.0131.263455 
 
Email: drugvigilance@filinf.it  
Website: www.drugvigilance.filinf.it  
 
Obligations of the Sponsor 
The sponsor-investigator assumes responsibility for appropriate reporting of serious unexpected 
suspected adverse reactions (SUSARs) occurred in the study and preparation and reporting of the 
development safety update report (DSUR) according to the current regulation. 
In particular, the Sponsor assumes responsibility for reporting to Italian Regulatory Authority through 
Eudravigilance, to all other Investigators that participate in the study and to the Ethic Committee of 
the coordinating center what described hereafter: 
- 
all relevant information about serious suspected unexpected adverse events (SUSAR) to be 
related to the study drugs that are fatal or life-threatening will be reported as soon as possible, 
and in any case no later than seven days after knowledge of such a case. Relevant follow-up 
information for these cases will be subsequently be submitted within an additional eight days 
- 
all other serious unexpected adverse events suspected (SUSAR) to be related to the study 
drugs will be reported as soon as possible, but within a maximum of fifteen days of first 
knowledge by the investigator; 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 57 of 79 
 
- 
reporting of all SUSARs related to the study drugs, as received by Janssen, to the Principal 
Investigators of all clinical sites participating in the trial. 
Moreover, the Sponsor-investigator will prepare and provide the copy of the DSUR to Italian 
Regulatory Authority and all relevant Ethics Committees.  
The FIL Pharmacovigilance will supply Janssen with a copy of all SAEs which involve exposure to a 
Janssen product within 24 hours of being made aware of the event regardless of whether or not the 
event is listed in the reference document (e.g., IB, SMPC). 
The FIL Pharmacovigilance will supply Janssen with a copy of all Pregnancy Reports and/or Special 
Reporting Situations and/or Product Quality Complaints (PQC) occurred during the study within 24 
hours of their knowledge of the event. 
The FIL Pharmacovigilance will provide Janssen with a copy of the annual development safety 
update report (DSUR) at the time of submission to the Regulatory Authority and Ethics Committees. 
 
PREGNANCY 
 
Females of Childbearing Potential 
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject or partners of male subjects occurring while the subject is on study 
drug, or within 3 months after the last dose of study treatment, are considered events to be reported 
by the study-site personnel within 24 hours of their knowledge of the event to FIL Pharmacovigilance 
on the appropriate Pregnancy Form. 
Email: drugvigilance@filinf.it 
Fax: +39.0131.263455  
Any subject who becomes pregnant during the study must be promptly withdrawn from the study 
and discontinue further study intervention. 
The exposure of any pregnant female (e.g., caregiver or pharmacist) to study drug is also an 
immediately reportable event.  
The female should be referred to an obstetrician/gynecologist preferably one experienced in 
reproductive toxicity for further evaluation and counseling. 
The Investigator will follow the female subject until completion of the pregnancy and must notify FIL 
immediately about the outcome of the pregnancy (either normal or abnormal outcome). 
Abnormal pregnancy outcomes (e.g., spontaneous or therapeutic abortion, fetal death, 
stillbirth, congenital anomalies, ectopic pregnancy) are considered serious adverse events 
and must be reported through www.drugvigilance.filinf.it within 24 hours of the Investigator’s 
knowledge of the event. 
All neonatal deaths that occur within 30 days from birth should be reported, without regard 
to causality, as SAEs. In addition, any infant death after 30 days that the Investigator suspects is 
related to the in-utero exposure to the study drug should also be reported to FIL within 24 hours of 
the Investigator’s knowledge of the event through www.drugvigilance.filinf.it. 
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the 
infant will be required. 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 58 of 79 
 
 
Male patients 
If a female partner of a male patient taking study drug becomes pregnant, the male patient taking 
study drug should notify the Investigator, and the pregnant female partner should be advised to call 
her healthcare provider immediately. 
If a pregnancy related event is reported in a female partner of a male subject, the investigator should 
determine whether the female partner is willing to release her medical information to FIL 
Pharmacovigilance and allow the pregnancy related event to be followed-up to completion. 
 
FOLLOW UP OF AES AND SAES 
Any SAE should be monitored until they are resolved or are clearly determined to be due to a 
patient’s stable or chronic condition or underlying condition. Any additional information known after 
the event has been initially reported should be sent to the FIL as soon as information becomes 
available via www.drugvigilance.filinf.it. 
All AEs, including ADRs must be documented, and the outcome must be followed-up until the return 
to normal or consolidation of the patient’s condition. 
Subjects withdrawn from the study due to any AE will be followed at least until the outcome is 
determined even if it implies that the follow-up continues after the patient has left the trial. 
 
PRODUCT QUALITY COMPLAINT HANDLING  
Any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, 
durability, reliability, safety, effectiveness, or performance of a product after it is released for 
distribution. A complaint is any indication of the failure of the product to meet consumer or user 
expectations for quality or to meet performance specifications. It may allege an adverse reaction, 
injury, or malfunction associated with the use of the product. It may also involve the design, literature, 
packaging, advertising, availability, physical appearance, or promotion of a product..  
Procedures 
All initial PQCs must be reported to the sponsor-investigator by the study-site personnel within 24 
hours after being made aware of the event. 
If the defect is combined with a SAE, the study-site personnel must report the PQC to the sponsor-
investigator according to the SAE reporting timelines. A sample of the suspected product should be 
maintained for further investigation. 
 
STATISTICAL CONSIDERATIONS  
 
STUDY DESIGN 
This is a prospective, multicenter, single arm, single-stage phase II trial in patients aged 18-75 years, 
with refractory/relapsed CD38 positive PTCL-NOS, AITL and TFH, with centrally assessed CD38 
expression ≥ 5%. 
It is expected for the current trial that D-GDP will improve the CR rate to 40% with an absolute 
improvement of 20%, while the toxicity rate is maintained at 30%. 
 
SAMPLE SIZE CALCULATION  
A'Hern's Single-Stage Phase II design will be used. The study sample size has been calculated 
according to the primary efficacy endpoint. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 59 of 79 
 
Based on data from the literature, the null hypothesis that the true proportion of CR after four courses 
of D-GDP is 0.20 will be tested against an alternative CR proportion of 0.40 with an absolute 
improvement of 0.20, considered clinically promising with the experimental treatment.  
Assuming a type I error rate of 5% and a power of 80% when the CR proportion is 40% overall 35 
patients will be accrued. The null hypothesis will be rejected if 12 or more CR out of 35 patients are 
observed after four courses of D-GDP. 
 
SAFETY MONITORING AND STOPPING RULES 
In order to monitor the safety and the activity of the treatment in small cohorts of patients, we will 
use the Bayesian approach of Thall et al. (1995) [53], as extended by Thall and Sung (1998) [54].  
Monitoring of relevant toxicity after 4 cycles of D-GDP will be done to ensure that it is not higher 
than an acceptable toxicity of 30% (as defined in the safety endpoints) and the monitoring of activity 
after 4 courses of D-GDP will be done to ensure that CR proportion is not lower than 40%.  
The prior probability of toxicity and activity are modeled by beta distributions [Beta (0.6,1.4) and Beta 
(0.8,1.2), respectively].  
The enrolment in the study will be stopped if the posterior probability of the treatment being more 
toxic or less active than expected is greater than 95%. 
Patients will be monitored according to the following stopping boundaries in cohorts of five patients, 
according to the rules summarized in the following Table: 
 
Number of 
patients 
enrolled 
Stop the enrollment if the 
cumulative relevant toxicities 
after 4 cycles  
are greater or equal to: 
Stop the enrollment if the number of 
cumulative CR after 4 cycles  
are lower or equal to: 
5 
4 
- 
10 
6 
1 
15 
9 
2 
20 
11 
4 
25 
13 
5 
30 
15 
7 
35 
17 
8 
 
 
STATISTICAL ANALYSIS PLAN 
 
Analysis population 
Both efficacy and safety analysis will be conducted on all patients receiving at least one dose of 
planned therapy including the investigational drug. 
 
Demographics and other baseline characteristics 
Demographic and baseline characteristics will be presented for all patients. Discrete variables will 
be summarized by frequencies and percentages. Continuous variables will be summarized by use 
of standard measures of central tendency and dispersion (mean and standard deviation or median 
and interquartile range). 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 60 of 79 
 
 
Final Efficacy analysis 
The primary efficacy analysis will be performed after enrolment of 35 patients. The primary efficacy 
analysis will consist of an estimate of CRR on the efficacy population after 4 cycles of D-GDP 
therapy, with 90% confidence intervals (according to 1-sided alpha error of 0.05). To conclude that 
the new treatment is promising, the minimum number of patients with a CR is 12/35.  
The time-to-event functions (OS and PFS) will be estimated by the Kaplan-Meier product-limit 
method. 
Subgroup analyses on primary efficacy parameter (CRR) will be performed to assess the role of 
daratumumab maintenance and to explore potential prognostic role of CD38 expression. A logistic 
regression model will be used and the effect (CRR) and its 95%CI will be presented.  
 
Final Safety analysis 
The analysis of safety assessments in this study will include summaries of the following categories 
of safety and tolerability data collected for each subject: 
- 
Drug Exposure 
- 
Adverse Events 
- 
ADRs and SAEs 
- 
AEs leading to withdrawal 
- 
Any Deaths 
Duration of study drug exposure, cumulative dose, and dose intensity will be summarized at patient 
level and at therapy cycle level. 
For safety analysis, both at patient level and at therapy cycle level, summaries of incidence rates 
(frequencies and percentages) and intensity of individual AEs by CTCAE v. 5.0 will be reported. 
Each patient will be counted only once within each preferred term during the therapy. If a patient 
experiences more than one AE within a preferred term during the therapy, only the AE with the 
greatest intensity will be included in the summaries. If, during the same therapy cycle, the patient 
experiences more than one AE within a preferred term, only the AE with the greatest intensity will 
be included in the summaries. 
According to categorization of CTCAE v 5.0, the cumulative incidence of first severe, life- 
threatening, fatal (CTCAE grade 3, 4 and 5) and/or SAEs (Infusion-related reactions) commencing 
during and up to 24 hours after study drug infusion and at any time during therapy and follow-up will 
be calculated; the cumulative incidence will be calculated using the method of Gooley et al [55], 
considering death from any cause as a competing event. 
 
Final analysis 
The results of this study will support the rationale of a phase III randomized trial if both efficacy and 
safety endpoints will be considered promising. 
 
INDEPENDENT DATA SAFETY MONITORING BOARD 
(DSMB) 
The FIL on its own initiative and responsibility set up an independent external DSMB. The DSMB 
consist in experts independent from the sponsor.  

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 61 of 79 
 
The selection of DSMB members is extremely important, as DSMB responsibilities relate to the trial 
safety participants. The ability of DSMBs is to provide the anticipated additional assurance of patient 
safety and trial integrity.  
The aim of the DSMB is to assess, at intervals during the course of the trial, the progress of the trial, 
the trial safety data and the trial outcome data with a view to recommending whether the trial should 
continue, be modified or be terminated. 
The DSMB composition include relevant expertise, experience in clinical trials and in serving on 
other DSMBs, and absence of serious conflicts of interest. The objectives and design of the trial and 
the scope of the responsibilities given to the DSMB determine the types of expertise needed for a 
particular DSMB.  
Roles of DSMB (suggested, not exclusive): 
1) To review ongoing safety and efficacy data throughout the study according to the efficacy 
and safety analyses described in paragraphs 18.4.3 and 18.4.4 and according to possible 
additional DSMB requests; 
2) To monitor evidence for treatment benefit and thus decide when/whether the main trial 
question has been answered; 
3) To monitor evidence for treatment harm (toxicity); 
4) To decide whether to recommend changes to the protocol; 
5) To decide whether to recommend that the trial continues to recruit participants or whether 
recruitment should be terminated; 
6) To review final analysis of the data; 
7) To discuss final data with PI and the sponsor. 
Following each meeting, the DSMB will prepare a report and may recommend changes in the 
conduct of the trial. 
 
INDEPENDENT EXTERNAL PATHOLOGY REVIEW 
An independent pathology panel will review the lymph node/tumor/bone marrow for confirmation of 
the diagnosis of cases classified by local pathologist as PTCL-NOS, AITL, TFH and for assessment 
of CD38 expression. The investigative site must submit the requested samples as part of the 
screening phase to allow for a histological review. 
The review process will be organized at the FIL designated central laboratory according to the 
procedures described in Appendix E.  
 
GOOD CLINICAL PRACTICE, QUALITY CONTROL & 
QUALITY ASSURANCE 
 
MONITORING, AUDITS AND INSPECTIONS 
During the study, the monitoring will be prevalently made by e-mail and telephone. The field monitor 
will visit the site, when needed, mainly in presence of data inconsistencies, to check the 
completeness of patient records, the accuracy of entries on the CRFs, the adherence to the protocol 
and to Good Clinical Practice and the progress of enrolment. Key study personnel must be available 
to assist the field monitor during these visits. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 62 of 79 
 
The investigator must maintain source documents for each patient in the study, consisting of case 
and visit notes (hospital or clinic medical records) containing demographic and medical information, 
laboratory data, electrocardiograms, and the results of any other tests or assessments. All 
information on CRFs must be traceable to these source documents in the patient's file. The 
investigator must also keep the original informed consent form signed by the patient (a signed copy 
is given to the patient). 
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the CRF entries. FIL Safety Monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, 
and the recording of data that will be used for all primary and safety variables. Additional checks of 
the consistency of the source data with the CRFs are performed according to the study-specific 
monitoring plan. No information in source documents about the identity of the patients will be 
disclosed. 
 
INVESTIGATOR(S) RESPONSIBILITIES 
Investigator(s) responsibilities are set out in the ICH guideline for Good Clinical Practice. The 
investigator must give the monitor access to relevant records to confirm the above.   
The Investigator(s) is responsible for keeping a record of all patients who sign an Informed Consent 
Form and are screened for entry into the study. For those patients who fail screening the reason(s) 
for exclusion must be recorded in the patient’s source documents. 
No procedure/assessment/measurement/test other than those outlined here, or in the schedule of 
study assessments, is to be performed without the prior written approval of Principal Investigator, or 
unless deemed by the investigator(s) as necessary for the patient’s medical care. Investigator(s) 
and/or authorized designee(s) must enter study data onto electronic CRFs supplied by FIL. The data 
on the CRF will be recorded in an anonymous manner to protect the patient’s identity by using a 
unique identifier that will prevent personal identifiable information. 
The Investigator(s), or a designated member of the Investigator’s staff, must be available at some 
time during monitoring visits to review data and resolve any queries and to allow direct access to the 
patient’s records (e.g., medical records, office charts, hospital charts, and study related charts) for 
source data verification. The CRFs must be completed as soon as possible after the patient’s visit, 
but no later than prior to each monitoring visit and be made available to the FIL representative(s) so 
that the accuracy and completeness may be checked. 
 
ETHICAL AND REGULATORY STANDARDS 
 
INDEPENDENT ETHICS COMMITTEE REVIEW APPROVAL 
This study will be conducted according to the Declaration of Helsinki Ethical Principles for Medical 
Research Involving Human Patients. The review of this protocol by the IEC and the performance of 
all aspects of the study, including the methods used for obtaining informed consent, must also be in 
accordance with principles enunciated in the declaration, as well as ICH Guidelines, Title 21 of the 
Code of Federal Regulations (CFR), Part 50 Protection of Human Patients and Part 56 Institutional 
Review Boards. Before implementing this study, the protocol, the proposed informed consent form 
and other information to patients, must be reviewed by a properly constituted IEC. A signed and 
dated statement that the protocol and informed consent have been approved by the IEC must be 
given to FIL before the study initiation. The names and occupations of the chairman and the 
members of the IEC must be supplied to FIL. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 63 of 79 
 
The FIL as sponsor of the study, together with site Investigator(s), will be responsible for preparing 
documents, wherever applicable, for submission to the relevant IEC and obtaining written approval 
for this study. The approval will be obtained prior to the initiation of the study. 
A copy of the IEC approval for the protocol and the Informed Consent is to be provided to FIL and 
site Investigator(s). The approval for both the protocol and informed consent must specify the date 
of approval, protocol number and version, or amendment number. 
The Investigator(s) is responsible for notifying the FIL Safety Monitoring Office and the IEC of any 
serious deviations from the protocol, or anything else that may involve added risk to patients. 
Any advertisements used to recruit patients for the study must be reviewed and approved by FIL and 
the IEC prior to use. 
Before the start of the study, the FIL will provide the IEC with current and complete copies of the 
following documents: 
1) 
final protocol and, if applicable, amendments; 
2) 
informed consent form (and any other written materials to be provided to the subjects); 
3) 
Investigator’s Brochure (or equivalent information) and amendments; 
4) 
information on compensation for study-related injuries or payment to subjects for 
participation in the study, if applicable; 
5) 
investigator’s curriculum vitae or equivalent information (unless not required, as 
documented by IEC); 
6) 
any other documents that the IEC requests to fulfil its obligation. 
During the study the FIL, in common accord with site investigators, will send the following documents 
to the IEC for their review and approval, where appropriate: 
1) 
protocol amendments; 
2) 
revision(s) to informed consent form and any other written materials to be provided to 
subjects; 
3) 
revisions to compensation for study-related injuries or payment to subjects for participation 
in the study, if applicable; 
4) 
Investigator’s Brochure amendments or new edition(s); 
5) 
summaries of the status of the study (at least annually or at intervals stipulated in guidelines 
of the IEC); 
6) 
reports of adverse events that are serious, unexpected and associated with the 
investigational drug; 
7) 
new information that may affect adversely the safety of the subjects or the conduct of the 
study; 
8) 
deviations from or changes to the protocol to eliminate immediate hazards to the subjects; 
9) 
report of deaths of subjects under the investigator's care; 
10) notification if a new investigator is responsible for the study at the site; 
11) any other requirements of the IEC. 
 
PROTOCOL AMENDMENTS APPROVAL 
Any amendment to this protocol that seems appropriate, as the study progresses will be submitted 
to the IEC for written approval before the implementation of the amended version. The written signed 
approval from the IEC should refer specifically to the investigator(s) and to the protocol number and 
title and mention any amendment numbers that are applicable. Amendments that are administrative 
in nature do not require IEC approval but will be submitted to the IEC for information purposes. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 64 of 79 
 
 
ADMINISTRATIVE PROCEDURES 
 
CURRICULUM VITAE 
An updated copy of the curriculum vitae of each investigator and sub-investigator will be provided to 
the FIL Start Up prior to the beginning of the study. 
 
CONFIDENTIALITY AGREEMENT 
All goods, materials, information (oral or written) and unpublished documentation provided to the 
investigators (or any company acting on their behalf), inclusive of this study, the patient case report 
forms are the exclusive property of FIL. 
They may not be given or disclosed by the investigator or by any person within his authority either 
in part or in totality to any unauthorized person without the prior written formal consent of FIL. 
It is specified that the submission of this study and other necessary documentation to the Ethics 
Review Committee or a like body is expressly permitted, the Ethics Committee members having the 
same obligation of confidentiality. 
The investigator shall consider as confidential and shall take all necessary measures to ensure that 
there is no breach of confidentiality in respect of all information accumulated, acquired or deduced 
during the trial, other than that information to be disclosed by law. 
 
RECORD RETENTION IN INVESTIGATING CENTERS 
The investigator must maintain all study records, patient files and other source data for the maximum 
period of time permitted by the hospital, institution or private practice. 
However national regulations should be taken into account, the longest time having to be considered. 
For studies performed in the European Community, the investigator is required to arrange for the 
retention of the patients’ identification codes according to the applicable laws and regulations on 
Clinical Trials. 
Any center will notify the sponsor before destroying any data or records. 
 
OWNERSHIP OF DATA AND USE OF THE STUDY RESULTS 
The sponsor has the ownership of all data and results collected during this study. In consequence, 
the sponsor reserves the right to use the data of the present study, either in the form of case report 
forms (or copies of these), or in the form of a report, with or without comments and with or without 
analysis, in order to submit them to the health authorities of any country. 
 
AUTHORSHIP 
The first results of the trial will be published after completion of data collection and evaluation of the 
primary endpoint. Partial or preliminary results can be published beforehand. Publication is to be 
initiated by the chairmen in charge of the study with approval of coordinators. 
Any publication in the form of a lecture, poster or article must be approved by the Scientific 
Committee of FIL before release. 
The authors will be proposed (according to the updated FIL publication rules) by the chairmen in 
charge of the study, approved by coordinators and finally decided by the Steering Committee of the 
study. 
All study data and publications are the property of the FIL. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 65 of 79 
 
 
INSURANCE COVERAGE 
The Investigator-sponsor of the Study must ensure that adequate insurance coverage is available to 
the patients, in accordance with the ICH Guidelines of Good Clinical Practice. Such coverage must 
extend to all damages deriving from the study, to the Protocol Study, with the exclusion of those 
attributable to willful misconduct or negligence of the institution or investigator. A copy, or excerpt, 
or insurer’s certificate, attesting the existence and amount of such coverage at least for the duration 
of the study must be supplied as part of the study documentation to the review and approval of the 
IEC.  
A specific insurance with company HDI Global SE has been concluded for patients enrolled in this 
study. No extra expenses, neither for therapies nor for clinical or laboratory procedures can be asked 
or expected to be paid by SSN or patients.  
 
PROTOCOL AMENDMENTS PROCEDURES 
It is specified that the appendices attached to this study and referred to in the main text of this stud, 
form an integral part of the study. 
No changes or amendments to this study may be made by the investigator or by the sponsor after 
the study has been agreed to and signed by both parties unless such change(s) or amendment(s) 
have been fully discussed and agreed upon by the investigator and the FIL.  
Any change agreed upon will be recorded in writing, the written amendment will be signed by the 
investigator and by the sponsor and the signed amendment will be appended to this study. 
Approval / advice of amendments by Ethics Review Committee and Competent Authorities are 
required prior to their implementation, unless there are overriding safety reasons. 
If the change or deviation increases risk to the study population, or adversely affects the validity of 
the clinical investigation or the subject's rights, full approval / advice must be obtained prior to 
implementation. For changes that do not involve increased risk or affect the validity of the 
investigation or the subject's rights, approval / advice may be obtained by expedited review, where 
applicable. 
In some instances, an amendment may require a change to a consent form. The investigator must 
receive approval/advice of the revised consent form prior to implementation of the change. In 
addition, changes to the case report forms, if required, will be incorporated in the amendment. 
 
DATA HANDLING AND RECORD KEEPING 
 
DATA/DOCUMENTS 
The investigator(s) must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the study drug, that is copies of CRFs and source documents original 
documents, data, and records (e.g., hospital records; clinical and office charts; laboratory notes; 
memoranda; patient’s diaries or evaluation checklists; pharmacy dispensing records; recorded data 
from automated instruments; copies or transcriptions certified after verification as being accurate 
copies; microfiches; photographic negatives, microfilm, or magnetic media; x-rays; patient files) and 
records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in 
the clinical study are complete, accurate, filed and retained. 
 
DATA MANAGEMENT 
Data will be entered into the clinical online database as per FIL SOPs. These data will be 
electronically verified through use of on-line checks during data entry, and through programmed edit 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 66 of 79 
 
checks specified by the clinical team. Discrepancies in the data will be brought to the attention of the 
clinical team, and investigational site personnel, if necessary, in the form of a Data Clarification Form 
(DCF) or a Query. Resolutions to these issues will be reflected in the database. An audit trail within 
the system will track all changes made to the data. 
 
RETENTION OF RECORDS 
The investigator(s) must maintain records of all study documents and supporting information relating 
to the conduct of the study. This documentation includes, but is not limited to, protocols, case report 
forms, advertising for patient participation, adverse event reports, patient source data, 
correspondence with health authorities and IECs, informed consent forms, investigator(s) curricula 
vitae, monitor visit logs, laboratory reference ranges, laboratory certification or quality control 
procedures and laboratory director curriculum vitae. Patient files and other source data must be kept 
for the maximum period of time permitted by the hospital, institution or private practice specified 
below. The study monitor must be consulted if the investigator(s) wishes to assign the study files to 
someone else, remove them to another location or is unable to retain them for a specified period. 
The investigator(s) must retain study records for the time period according to local laws or 
requirements, whichever is longer. The monitor will inform the investigator(s) of the dates for 
retention. All study documents should be made available if required by relevant health authorities.  
 
PRIVACY OF PERSONAL DATA 
The collection and processing of personal data from subjects enrolled in this study will be limited to 
those data that are necessary to investigate the efficacy, safety, quality, and utility of the 
investigational product used in this study. These data must be collected and processed with 
adequate precautions to ensure confidentiality and compliance with applicable data privacy 
protection laws and regulations. 
The investigator-sponsor ensures that the personal data will be: 
1) 
processed fairly and lawfully; 
2) 
collected for specified, explicit, and legitimate purposes and not further processed in a way 
incompatible with these purposes; 
3) 
adequate, relevant, and not excessive in relation to said purposes; 
4) 
accurate and, where necessary, kept current. 
Explicit consent for the processing of personal data will be obtained from the participating subject 
(or his/her legally acceptable representative) before collection of data. Such consent should also 
address the transfer of the data to other entities and to other countries. The subject has the right to 
request through the investigator access to his/her personal data and the right to request rectification 
of any data that are not correct or complete. Reasonable steps should be taken to respond to such 
a request, taking into consideration the nature of the request, the conditions of the study, and the 
applicable laws and regulations. 
Patients will be registered in the study via web site at the end of their staging and before beginning 
the treatment. The name of the patient will not be asked for not recorded at the Data Center. A 
sequential identification number will be automatically attributed to each patient registered in the trial. 
This number will identify and must be included on all case report form.  

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 67 of 79 
 
 
REFERENCES 
1.  
Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic 
and Lymphoid Tissues. WHO Classification of Tumours, Revised 4th Edition, Volume 2, 
Revised 4t. Lyon, France: IARC Press, 2017. 
2.  
Foss FM, Zinzani PL, Vose JM et al. Peripheral T-cell lymphoma. Blood 2011; 117(25):6756–
67. 
3.  
Coiffier B, Federico M, Caballero D et al. Therapeutic options in relapsed or refractory 
peripheral T-cell lymphoma. Cancer Treat Rev 2014; 40(9):1080–1088. 
4.  
Zinzani PL, Magagnoli M, Bendandi M et al. Therapy with gemcitabine in pretreated peripheral 
T-cell lymphoma patients. Ann Oncol 1998; 9(12):1351–3. 
5.  
Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. 
Br J Haematol 2001; 113(1):185–7. 
6.  
Zinzani PL, Venturini F, Stefoni V et al. Gemcitabine as single agent in pretreated T-cell 
lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010; 21(4):860–863. 
7.  
Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or 
refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 
2012; 30(18):2190–6. 
8.  
Horwitz SM, Advani RH, Bartlett NL et al. Objective responses in relapsed T-cell lymphomas 
with single-agent brentuximab vedotin. Blood 2014; 123(20):3095–100. 
9.  
Coiffier B, Pro B, Prince HM et al. Results from a pivotal, open-label, phase II study of 
romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. 
J Clin Oncol 2012; 30(6):631–6. 
10.  
Coiffier B, Pro B, Prince HM et al. Romidepsin for the treatment of relapsed/refractory 
peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol 
Oncol 2014; 7:11. 
11.  
O’Connor OA, Horwitz S, Masszi T et al. Belinostat in patients with relapsed or refractory 
peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study. J Clin 
Oncol 2015; 33(23):2492–2499. 
12.  
O’Connor OA, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory 
peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 2011; 
29(9):1182–1189. 
13.  
Zaja F, Tabanelli V, Agostinelli C et al. CD38, BCL-2, PD-1, and PD-1L expression in nodal 
peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? Am J Hematol 
2017; 92(1):E1–E2. 
14.  
Santonocito AM, Consoli U, Bagnato S et al. Flow cytometric detection of aneuploid CD38(++) 
plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest 
in multiple myeloma patients. Leuk Res 2004; 28(5):469–77. 
15.  
Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 
cases of multiple myeloma. Am J Clin Pathol 2004; 121(4):482–8. 
16.  
de Weers M, Tai Y-T, van der Veer MS et al. Daratumumab, a novel therapeutic human CD38 
monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J 
Immunol 2011; 186(3):1840–8. 
17.  
Lammerts van Bueren J, Jakobs D, Kaldenhoven N et al. Direct in Vitro Comparison of 
Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and 
Ab79. Blood 2014; 124(21):3474 LP – 3474. 
18.  
Overdijk MB, Verploegen S, Bögels M et al. Antibody-mediated phagocytosis contributes to 
the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple 
myeloma. MAbs 2015; 7(2):311–21. 
19.  
Overdijk MB, Jansen JHM, Nederend M et al. The Therapeutic CD38 Monoclonal Antibody 
Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking. J 
Immunol 2016; 197(3):807–13. 
20.  
Krejcik J, Casneuf T, Nijhof IS et al. Daratumumab depletes CD38+ immune regulatory cells, 
promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016; 
128(3):384–94. 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 68 of 79 
 
21.  
Bride KL, Vincent TL, Im S-Y et al. Preclinical efficacy of daratumumab in T-cell acute 
lymphoblastic leukemia. Blood 2018; 131(9):995–999. 
22.  
Lonial S, Weiss BM, Usmani SZ et al. Daratumumab monotherapy in patients with treatment-
refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 
387(10027):1551–60. 
23.  
Lokhorst HM, Plesner T, Laubach JP et al. Targeting CD38 with Daratumumab Monotherapy 
in Multiple Myeloma. N Engl J Med 2015; 373(13):1207–19. 
24.  
Dimopoulos MA, Oriol A, Nahi H et al. Daratumumab, Lenalidomide, and Dexamethasone for 
Multiple Myeloma. N Engl J Med 2016; 375(14):1319–1331. 
25.  
Palumbo A, Chanan-Khan A, Weisel K et al. Daratumumab, Bortezomib, and Dexamethasone 
for Multiple Myeloma. N Engl J Med 2016; 375(8):754–66. 
26.  
Chari A, Suvannasankha A, Fay JW et al. Daratumumab plus pomalidomide and 
dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017; 130(8):974–981. 
27.  
Mateos M-V, Dimopoulos MA, Cavo M et al. Daratumumab plus Bortezomib, Melphalan, and 
Prednisone for Untreated Myeloma. N Engl J Med 2018; 378(6):518–528. 
28.  
Morabito F, Damle RN, Deaglio S et al. The CD38 ectoenzyme family: advances in basic 
science and clinical practice. Mol Med 2006; 12(11–12):342–4. 
29.  
Patten PEM, Buggins AGS, Richards J et al. CD38 expression in chronic lymphocytic 
leukemia is regulated by the tumor microenvironment. Blood 2008; 111(10):5173–81. 
30.  
Konoplev S, Medeiros LJ, Bueso-Ramos CE et al. Immunophenotypic profile of 
lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol 2005; 
124(3):414–20. 
31.  
Parry-Jones N, Matutes E, Morilla R et al. Cytogenetic abnormalities additional to t(11;14) 
correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may 
influence prognosis: A study of 60 cases by FISH. Br J Haematol 2007; 137(2):117–124. 
32.  
Keyhani A, Huh YO, Jendiroba D et al. Increased CD38 expression is associated with 
favorable prognosis in adult acute leukemia. Leuk Res 2000; 24(2):153–9. 
33.  
Marinov J, Koubek K, Starý J. Immunophenotypic significance of the “lymphoid” CD38 antigen 
in myeloid blood malignancies. Neoplasma 1993; 40(6):355–8. 
34.  
Suzuki R, Suzumiya J, Nakamura S et al. Aggressive natural killer-cell leukemia revisited: 
large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18(4):763–70. 
35.  
Wang L, Wang H, Li P et al. CD38 expression predicts poor prognosis and might be a potential 
therapy target in extranodal NK/T cell lymphoma, nasal type. Ann Hematol 2015; 94(8):1381–
8. 
36.  
Hari P, Raj R V, Olteanu H. Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell 
Lymphoma. N Engl J Med 2016; 375(15):1501–1502. 
37.  
Chau I, Watkins D, Cunningham D. Gemcitabine and Its Combinations in the Treatment of 
Malignant Lymphoma. Clin Lymphoma 2002; 3(2):97–104. 
38.  
Emmanouilides C, Colovos C, Pinter-Brown L et al. Pilot study of fixed-infusion rate 
gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory 
lymphoma. Clin Lymphoma 2004; 5(1):45–9. 
39.  
Park B-B, Kim WS, Suh C et al. Salvage chemotherapy of gemcitabine, dexamethasone, and 
cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a 
consortium for improving survival of lymphoma (CISL) trial. Ann Hematol 2015; 94(11):1845–
51. 
40.  
Qi F, Dong M, He X et al. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage 
chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not 
otherwise specified. Ann Hematol 2017; 96(2):245–251. 
41.  
Horwitz S, Ansell S, Weiyun Z et al. NCCN Clinical Practice Guidelines in Oncology. T-Cell 
Lymphomas. 2018:Version 2.2019. 
42.  
Ng M, Waters J, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone (GEM-
P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J 
Cancer 2005; 92(8):1352–7. 
43.  
Arkenau H-T, Chong G, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone 
for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 69 of 79 
 
experience. Haematologica 2007; 92(2):271–2. 
44.  
Yim K-L, Ashley S. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) 
combination treatment for non-Hodgkin T cell lymphoma. Med Oncol 2012; 29(5):3535–9. 
45.  
Yao Y, Tang Y, Zhu Q et al. Gemcitabine, oxaliplatin and dexamethasone as salvage 
treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk 
Lymphoma 2013; 54(6):1194–200. 
46.  
Connors JM, Villa D, Klasa R et al. The Use Of GDP (Gemcitabine, Dexamethasone and 
Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas. Blood 2013; 
122(21):1804 LP – 1804. 
47.  
Dong M, He X-H, Liu P et al. Gemcitabine-based combination regimen in patients with 
peripheral T-cell lymphoma. Med Oncol 2013; 30(1):351. 
48.  
Crump M, Kuruvilla J, Couban S et al. Randomized Comparison of Gemcitabine, 
Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin 
Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory 
Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014; 32(31):3490–3496. 
49.  
Rizzo JD, Brouwers M, Hurley P et al. American Society of Clinical Oncology/American 
Society of Hematology clinical practice guideline update on the use of epoetin and 
darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28(33):4996–5010. 
50.  
Smith TJ, Bohlke K, Lyman GH et al. Recommendations for the Use of WBC Growth Factors: 
American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 
33(28):3199–3212. 
51.  
Chapuy CI, Nicholson RT, Aguad MD et al. Resolving the daratumumab interference with 
blood compatibility testing. Transfusion 2015; 55(6 Pt 2):1545–54. 
52.  
Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging, 
and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. 
J Clin Oncol 2014; 32(27):3059–3068. 
53.  
Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical 
trials with multiple outcomes. Stat Med 1995; 14(4):357–79. 
54.  
Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring 
multiple outcomes in clinical trials. Stat Med 1998; 17(14):1563–80. 
55.  
Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the 
presence of competing risks: new representations of old estimators. Stat Med 1999; 
18(6):695–706. 
56.  
Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6):649–655. 
57.  
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976; 16(1):31–41. 
58.  
Bossard C, Dobay MP, Parrens M et al. Immunohistochemistry as a valuable tool to assess 
CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood 
2014; 124(19):2983–6. 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 70 of 79 
 
 
APPENDICES 
APPENDIX A: 
ECOG PERFORMANCE STATUS 
SOURCE: Oken MM et al, Toxicity And Response Criteria Of The Eastern Cooperative Oncology 
Group. Am J Clin Oncol 5:649-655, 1982 [56]. 
 
Grade 
ECOG 
0 
Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light housework, office work 
2 
Ambulatory and capable of all selfcare but unable to carry out any work activities. Up 
and about more than 50% of waking hours 
3 
Capable of only limited selfcare, confined to bed or chair more than 50% of waking 
hours 
4 
Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair 
5 
Dead 
 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 71 of 79 
 
APPENDIX B: 
CREATININE CLEARANCE CALCULATION 
 
SOURCES: Cockcroft DW, Gault MH, Prediction of creatinine clearance from serum creatinine. 
Nephron 16, 31-41,1976 [57]. 
 
Creatinine clearance for men and women will be calculated according to the Cockcroft-Gault 
formula as follows: 
 
 
In men: 
 
 
 
 
 
In women:  
 
 
 
 
 
Note:  
Age (in years), weight (in kg), serum-creatinine (in mg/dL)  
72 (normalized to 72 kg body weight and a body surface of 1.72 m2). 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 72 of 79 
 
APPENDIX C: 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS V. 5.0 
 
In the present study, adverse events and/or adverse drug reactions will be recorded according to 
the: Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. 
Click on CTCAE, version 5.0 to download the document in pdf. 
 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 73 of 79 
 
APPENDIX D: 
RESPONSE ASSESSMENT BY CT AND PET SCANS  
SOURCE: Cheson et al., J Clin Oncol. 2014 Sep 20;32(27):3059-68 [52]. 
 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 74 of 79 
 
 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 75 of 79 
 
APPENDIX E: 
GUIDELINES FOR PATHOLOGY REVIEW 
 
The review process will be organized at the FIL designated central laboratory according to the 
procedures below described. Lymph node/tumor/bone marrow biopsy documenting relapse of 
PTCL-NOS/AILT/other nodal lymphoma of TFH cell origin, or the more recent biopsy in the case of 
refractory patients, will be used for central review and for CD38 expression evaluation in 
immunohistochemistry. Central review and CD38 expression assessment are  mandatory for the 
study. 
The investigative site must submit the requested samples as part of the screening phase to allow for 
an upfront histological review and for CD38 expression evaluation by immunohistochemistry.  
Samples shipment will be set up by FIL  
For each patient a formalin-fixed paraffin embedded (FFPE) tissue block should be provided to the 
central laboratory. Sites are encouraged to provide a block, since some nuclear antigens to be tested 
are labile, and the risk for false negative results on cut sections is high. 
The block will be promptly returned to the local site upon completion of the central review process 
and CD38 assessment. 
In the case a block is absolutely not available, the site can choose one on the two following options: 
a) to send 20 unstained sections; 
b) to send one H&E or GIEMSA stained slide from each block, and all immunostains performed 
for local diagnosis plus 15 unstained sections. The institution’s H&E, GIEMSA and 
immunostains will be returned promptly after the review is done. 
In both cases, an anonymized copy of the local diagnostic reports, including the description, the final 
diagnosis, and the immunohistochemical and/or flow cytometry results and molecular results, if done, 
are also to be provided. 
Tests to be performed at central laboratory 
Central review and confirmation of diagnosis 
All tumor samples will be centrally revised according to the 2017 revised edition of the WHO-
classification of Tumours of the Haematopoietic and Lymphoid Tissues [1]. 
Samples will be tested with the following panel of markers: CD2, CD3, CD4, CD5, CD7, CD8, CD30, 
CD15, CD20, CD21, PD-1, BCL6, CD10, CXCL13, TIA-1, Granzyme B, perforin, FOXP3, Ki-67/MIB-
1, and CD38.  
Evaluation of CD38 expression 
Immunohistochemical assessment (ICH) of expression of CD38 will be performed on fresh sections 
cut from the paraffin block (or on unstained sections), and the percentage of positive tumor cells will 
be scored according to Bossard C. et al [58] as follows: 4: >75%; 3: 50-75%; 2: 25-49%; 1: 5-24%; 
0: <5%. 
Only patients with a percentage of CD38 positive tumor cells ≥ 5% (score ≥ 1) will receive the study 
treatment, while cases with an insufficient amount of tumor tissue cells (score =0) will be considered 
as “not evaluable” and will not be included into the study. 
Details on results of centralized review and CD38 expression assessment will be collected on a 
dedicated CRF. 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 76 of 79 
 
 
FIL designated central laboratory for central review and CD38 expression assessment: 
Prof. Stefano Pileri, Dr. Valentina Tabanelli, Dr. Stefano Fiori 
Divisione di Diagnosi Emolinfopatologica 
Building IEO1, 1° piano 
IEO - Istituto Europeo di Oncologia 
via Ripamonti 435, Milano 
Phone: +39 02 57489522 
Fax: +39 02 94379320 
Email: stefano.pileri@ieo.it; divisione.emolinfopatologia@ieo.it 
The laboratory has entered into an agreement with FIL to carry out the centralized review of the 
samples of patients registered in the trial. 
 
 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 77 of 79 
 
APPENDIX F: 
REFERENCE SAFETY INFORMATION DARATUMUMAB 
(Serious Expected Terms Associated with Daratumumab Coded by MedDRA version 20.0) 
IB edition 15.0. Approval date: 14 Dec 2018. Data cut-off date: evaluated safety data from 8 
clinical studies (GEN501,GEN503, MMY1001, MMY1002, MMY2002, MMY3003, MMY3004, and 
MMY3007) and post-marketing experience up to 15 Nov 2018 
 
 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 78 of 79 
 
 
 
 
 
 

MD01-02_I01_PRDS00 
 
 
FIL_Dara-GDP, version 1.0 of March 29, 2019  
 
Page 79 of 79